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Science knows no country, because knowledge belongs to 
humanity, and is the torch which illuminates the world.  
Louis Pasteur 
 
What we observe is not nature itself, but nature exposed 
to our method of questioning. 
Werner Heisenberg 
 
  
ABSTRACT 
Exosomes are nano-sized membrane vesicles derived from the late endosomal compartment. 
They are capable of transferring proteins, lipids and RNA between cells. B cell and dendritic 
cell (DC)-derived exosomes express major histocompatibility complex (MHC) class I and II, 
as well as costimulatory molecules (CD80/86) and can initiate T cell responses. Several 
clinical trials have shown DC-derived exosome-based cancer immune therapy to be safe but 
limited in inducing antigen-specific T cells. In contrast, tumour cell-derived exosomes can 
express immune inhibitory molecules and play an important role in spreading oncogenic 
activity by carrying tumour antigens, inducing angiogenesis at distant sites and preparing 
tissues for metastasis. This thesis aimed at I) analysing how to enhance the immunogenicity 
of exosomes for therapy, II) investigating whether MHC complexes on exosomes are needed 
to induce an anti-tumour immune response, III) comparing microvesicles and exosomes side 
by side for their immunogenic capacity, IV) understanding the metastatic process induced by 
tumour-derived exosomes from bladder cancer patients and whether certain exosomal 
proteins can be used as markers for diagnosis and prognosis. 
 
Study I reveals that exosomes loaded with the NKT cell ligand alpha-galactosylceramide 
(αGC) and the model antigen ovalbumin (OVA) activate NKT cells, induce strong NK and γδ 
T cell innate immune responses, and induce OVA-specific T and B cell responses far better 
than only OVA-loaded exosomes. Exosomes loaded with αGC/OVA decreased tumour 
growth and increased median survival compared to exosomes loaded with OVA only or 
soluble αGC + OVA alone in a B16 melanoma model. This study demonstrates how to 
increase the immunogenicity of DC-derived exosomes for cancer treatment. 
 
Study II demonstrates that exosomal MHC class I is dispensable for the induction of antigen-
specific T cell responses if whole OVA is present. We show that OVA-loaded DC-derived 
exosomes from MHCI-/- mice induce antigen-specific T cells to the same extent as wild type 
exosomes. Even exosomes with MHC class I and II mismatch induced tumour-infiltrating 
CD8+ T cells and increase survival in a B16 melanoma model. This study provides new 
opportunities for the design of allogeneic exosome-based vaccines and therapies.  
 
Study III compares microvesicles (MV) and exosomes from OVA-exposed DCs side by side 
for their capacity to induce OVA-specific immune responses in vivo. MV and exosomes 
express similar surface markers but only exosomes induced OVA-specific CD8+ T cells and 
OVA-specific IgG antibodies. In contrast, MV induced a higher number of plasma cells. 
Finally, we found that exosomes contain more OVA compared to MV. We conclude that 
exosomes from DCs are superior in inducing antigen-specific immune responses in vivo 
compared to MVs, while MVs might activate the immune system unspecifically.  
 
Study IV evaluates the proteomic profile of exosomes from tumour tissue explants and urine 
from urinary bladder cancer patients. We show that exosomes from malignant or benign 
tissue can be distinguished by the proteomic profile and are involved in platelet, metabolic 
and immune signalling networks. We show that, even if no tumour is left, exosomes can 
express a metastatic memory phenotype which might be involved in cancer progression.  
 
In summary, this thesis gives new insights into how to design vesicle-based cancer vaccines 
and provide new opportunities for the use of allogeneic DC-derived exosomes in patients. In 
addition, we demonstrate that exosomes isolated from the urine of urinary bladder cancer 
patients express specific markers for malignancy, which provides new possibilities for 
diagnostic strategies.    
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM IN CANCER 
1.1.1 Historical Overview of Tumour Immunology 
The earliest reference of immunity is from 430 BC when a Greek historian in Athens 
described a plague outbreak. He described that people who survived the illness can nurse 
infected people without suffering from the infection a second time. Interestingly, time passed 
until the concept of immunity was described a second time. In the 15th century, the Chinese 
prevented smallpox infections by using dried crusts from smallpox pustules as an inhalation 
vaccine or put small pieces into cuts in the skin (variolation). This was a huge success in 
prevention of new infections; however, severe and fatal reactions after variolation were 
occurring [1]. 
In 1798 Edward Jenner made an important discovery; he realized that milkmaids who were in 
contact with cows suffering from cowpox were immune against severe smallpox infections. 
He injected an eight-year old boy with the fluid from a cowpox pustule and infected the boy 
later on with smallpox. Surprisingly and fortunately, the boy did not become sick. In the 
summer of 1881, Louis Pasteur noticed that cholera bacteria, from an old culture forgotten 
over summer, gave chickens only minor symptoms and more importantly protected them 
from getting infected a second time with a fresh stock of cholera bacteria. He described the 
concept of vaccination and further developed his findings for other diseases and used 
weakened or attenuated strains as a vaccine. This is considered the beginning of modern 
immunology [2]. In 1883 Elie Metchnikoff described a white blood cell, which was able to 
take up microorganisms or other small particles. He named it phagocyte and discovered the 
cellular part of the immune system. During the same time in the late 19th century, von 
Behring and Kitasato discovered that the serum from animals previously infected with 
diphtheria could transfer immunity to unimmunized animals. They discovered the humoral 
part of the immune system.  
Interestingly, already in 1891 a surgeon treated his cancer patients with bacterial products, 
which induced inflammation and led to a reduction of the tumour mass. However, for a long 
time engagement of the immune system to fight against cancer was doubted due to poor 
results [3]. In the 1930s Elvin Kabat showed that the transfer of immunity was mediated by 
gamma globulins (today immunoglobulins). Hence, the concept of humoral immunity was 
born and led to many new treatment options and the term passive immunity was established. 
Vaccines, on the other hand, are referred to as active immunity, engaging the immune 
system´s possibility to react to an antigen and to develop immunity. In the late 1940s the first 
chemotherapy was approved by the US food and drug administration (FDA). This was the 
time when the understanding of the involvement of the immune system in cancer grew. 
Edward J. Foley discovered that inbred mice transplanted with a tumour, followed by tumour 
removal, were more resistant to a second transplantation. In 1959, the tuberculosis vaccine 
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Bacillus Calmette-Guérin (BCG) inhibited tumour growth in mice. BGC installation is, still 
up to this date, a potent therapy in non-invasive superficial bladder cancer.  
Today, researchers are pursuing several lines of immunology-based cancer therapeutics 
including vaccines, check point inhibitors, depleting antibodies and chimeric antigen receptor 
(CAR) T cells. In addition, they are still trying to understand how the body’s own immune 
system can be used to fight cancer, how tumour cells influence the tumour microenvironment 
and how metastasis develop at distant sites. The understanding of how to trigger a potent 
cellular memory and antibody response is a big challenge in the development of anti-cancer 
immunotherapies and cancer vaccines. The development and identification of new adjuvants 
(e.g. nanoparticles) and the use of neoantigens to induce specific anti-tumour immune 
response are ongoing.  
 
1.1.2 Cancer and the Immune System 
For a long time engagement of the immune system to fight cancer was doubted due to poor 
results in several clinical trials. The field changed mid-1990s when it was shown that 
transplanted tumours grow better in mice treated with a neutralizing antibody against IFNγ 
[4] and mice lacking a functional IFNγ pathway or T cell compartment were more susceptible 
to chemically induced sarcomas [5, 6]. This was the first time shown that the immune system 
plays a crucial role in controlling tumour growth. In addition, the immune system also defines 
the characteristics of the tumour. 3-methylcholanthrene (MCA)-induced tumours grown in 
Rag2-/- mice and transplanted into naïve syngeneic mice led to tumour eradiation. In contrast, 
MCA-induced sarcomas grown in immunocompetent syngeneic mice grew progressively 
when transplanted into naïve syngeneic mice [7]. These results demonstrate that tumours are 
immunogenic and induce an anti-tumour immune response, which can eliminate cancer cells. 
Thus, the concept of immunoediting was developed. Cancer immunoediting is a dynamic 
process, which consists of three different phases, the elimination phase, equilibrium phase 
and escape phase. 
Elimination phase 
The elimination phase is characterized by the recognition of transformed tumour cells by the 
innate and adaptive immune system. Mice lacking NKT cells (CD1d-/- and Jα18-/- mice), NK 
cells or αβ T and γδ T cells are more susceptible to carcinogen induced tumours [8-10]. The 
tumour microenvironment during the elimination phase is pro-inflammatory and 
characterized by expression of interferons. IFNγ can on one hand upregulate MHC class I 
expression of tumour cells, leading to recognition by CD8+ T cells or activate the host´s 
immune system to fight cancer [7]. Mice lacking parts of the cytotoxic pathway like perforin, 
TRAIL or FasL are also more susceptible to age induced tumours [11-13].  
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Equilibrium 
Many tumours are poorly immunogenic and the balance between cancer cell proliferation and 
destruction is called equilibrium phase. This phase is mainly mediated by the adaptive 
immune system. Koebel and colleagues showed in 2007 that cancer lesions induced by low 
doses of carcinogens, rapidly grew out once the CD4+ and CD8+ cells and/or IFNγ were 
depleted. However, this was not the case when depleting NK cells or NK cell function (using 
anti-NKG2D, anti-TRAIL antibodies) [14].  
Escape phase 
In the escape phase the immune system has failed to eradicate tumour cells and they can 
divide rapidly and acquire different genetic alterations. The tumour microenvironment 
changes to be immunosuppressive, mediated by regulatory T cells, myeloid-derived 
suppressor cells (MDSC) and tumour-associated macrophages (TAM), all inhibiting T cell 
activation. There are different immune escape strategies, (I) tumour cells can be rendered 
invisible to the tumouricidal CD8+ T cells if they do not express neoantigens or downregulate 
specific tumour-associated antigens (TAA). (II) Furthermore, cancer cells secret soluble 
factors, which can influence the tumour-associated immune cells. They can secrete soluble 
NKG2D ligands, which block activating NK cell receptors [15], or vascular endothelial 
growth factor (VEGF), which leads to enhanced angiogenesis and inhibits the maturation 
status of DCs [16]. Tumour cells can also secrete IL-10 or TGFβ, which act as inhibitory 
cytokines, promote differentiation of regulatory T cells and skew the immune system towards 
a Th2 phenotype [17]. The expression of the enzyme IDO by tumour cells and antigen 
presenting cells leads to production of immunoinhibitory metabolites, which induce T cell 
anergy and apoptosis [18]. (III) Tumour cells can also influence the immune system by 
downregulating molecules involved in T cell recognition (MHC class I, β2m) [19, 20] or 
express mutated forms of certain death receptors [21]. Interestingly, tumour cells can also 
express immune inhibitory ligands like PD-L1, which leads to dampening of cytotoxic T cell 
responses or apoptosis of T cells [22]. This whole orchestra of suppressive cells and 
cytokines leads to the failure of anti-tumour immunity and to cancer progression.  
 
1.1.3 Dendritic Cells 
1.1.3.1 General overview 
Dendritic cells (DCs) are bridging the innate with the adaptive immune system by 
recognizing antigens and inducing antigen-specific immune responses. DCs have been shown 
to be the most efficient antigen presenting cells in stimulating naïve T cells [23]. They are 
specialized in the uptake and processing of antigens in order to present peptides on MHC 
complexes to T cells [24]. DCs are located at pathogen exposed sites such as mucosal 
surfaces, where they constantly sample the environment for pathogens. After they have 
encountered a pathogen/antigen they differentiate into a mature phenotype, upregulate CCR7, 
 4 
MHC class I and II and costimulatory molecules [23] and migrate to the regional lymph node 
to activate T cells.  
DCs take up antigens through different mechanisms such as receptor-mediated endocytosis 
(mainly lectin receptors recognizing carbohydrates), phagocytosis and macropinocytosis. 
After uptake, proteins are digested in the phago-lysosome and peptides are loaded onto MHC 
class II molecules in the endocytic pathway for presentation to CD4+ T cells. On the other 
hand, MHC class I destined peptides are produced in the cytosol by degradation of 
endogenous proteins or foreign antigens by the proteasome. These peptides are transported 
via the TAP transporter into the lumen of the rough endoplasmatic reticulum (rER) where 
they can bind MHC class I complexes (Figure 1). However, also exogenous antigens can be 
loaded onto MHC class I molecules by a process called cross-presentation. Two pathways are 
suggested for cross-presentation. In the cytosolic pathway antigens are transferred from the 
endosome into the cytosol. DCs, compared to macrophages, have a relatively mild endosome 
and low levels of lysosomal proteases, therefore intact antigens can escape the endosome. In 
the cytosol, they are degraded by the proteasome and are transferred into the ER through the 
TAP transporter to be loaded on MHC class I molecules [25, 26]. In the vacuolar pathway 
antigens are directly degraded in the endocytic compartment and loaded onto MHC class I 
molecules [27].  
 
Figure 1: Processing of endogenous and exogenous antigens by dendritic cells and loading of MHC 
class I and II molecules. 
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DCs are a heterogeneous group of cells and differ in their capacity to regulate Th1 or Th2 
immunity. Certain subsets can induce high levels of type I interferons or cross-present 
antigens to CD8+ T cells. Depending on the exogenous stimuli and subset, DCs will respond 
differently by producing different cytokines or upregulating certain genes [28-30]. For 
example, virus-like particles from human papilloma virus induce IFNγ expression in CD8α+ 
DCs but Th2 cytokines in CD8α-CD11b+CD11c+ DCs [31]. LPS and inflammatory cytokines 
such as TNFα or CD40 ligand can induce DC maturation, which leads to expression of 
molecules involved in T cell activation [32, 33]. DCs activated through TLR ligands are able 
to produce IL-12 and can activate other DCs, which have not been stimulated by a TLR 
ligand. However, these DCs fail to produce IL-12 but upregulate MHC and costimulatory 
molecules and can activate naïve T cells in the same manner as directly activated by TLR 
ligands. Interestingly, T cells activated by indirectly activated DC cannot exert Th1 effector 
functions [34].  
1.1.3.2 Dendritic Cell Therapy in Cancer 
As described above, the goal of tumour immunotherapy is to activate the patient´s own 
immune system to elicit a potent anti-tumour immune response. Currently, monoclonal 
antibody therapy against CTLA-4 in metastatic melanoma showed promising results and was 
approved by FDA in 2011. However, these therapies are only effective with a pre-existing 
anti-tumour immune response in the patient [35]. The combination of checkpoint blockade 
and cell therapy for the induction of tumour-specific T cells might be an attractive approach. 
The goal of DC therapy in cancer is on one hand to induce tumour-specific CD4+ and CD8+ T 
cells, which can regulate tumour growth and on the other hand the induction of memory T 
cells to prevent relapses. Many clinical trials using DC therapy were shown to be safe with 
low side effects and no immune related toxicity but with suboptimal clinical success [36]. In 
contrast, checkpoint blockade antibodies can induce severe immune related side effects and 
autoimmunity [37]. DC vaccination induces tumour-specific T cells in many patients [38], 
however, the clinical efficacy is still very limited, even though there are patients with 
complete remission. Thus, DC vaccination needs further refinement to increase the 
frequencies of responders, possibly by finding biomarkers for personalized treatment 
strategies [36]. The low efficacy might be due to a strong immune suppressive tumour 
microenvironment, limited T cell migration into the tumour and suboptimal selection of 
patients, where mainly patients with advanced cancer and poor prognosis have been treated 
so far. Nevertheless, current treatment protocols (chemotherapy, radiotherapy) in these 
patients show similar clinical efficacy as DC therapy [36]. In conclusion, different simulation 
protocols of DCs and combination therapies need to be further investigated.  
Currently, there are many different protocols used in clinical trials. Often monocyte-derived 
DCs cultured with IL-4 and matured with pro-inflammatory cytokines such as TNFα, IL-1β, 
IL-6 and prostaglandin E2 and/or TLR ligands are used in DC-based cancer therapy. The 
maturation status of the DC is important for the clinical outcome. Matured DC showed better 
results in patients with prostate cancer, melanoma and glioma [39, 40]. Interestingly, DC 
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matured with TNFα, IL-1β, IFNγ, IFNα and polyI:C showed good clinical activity [41]. 
Currently, also the use of different DC subsets, such as Langerhans-like DCs, which are very 
efficient in simulating cytotoxic T cells, are evaluated [42, 43]. In summary, DC-based 
therapies need further refinement to show good clinical efficacy and to elicit strong T cell 
responses. Selection of the right patient group might improve clinical responses and survival.  
 
1.1.4 CD8+ T Cell Responses 
Upon antigen encounter DCs may activate CD8+ and CD4+ T cells. How the interaction 
between CD4+ and CD8+ and DC is occurring is still under debate. The “three cell 
interaction” model proposes that CD4+ and CD8+ T cells must bind to the same DC in order 
to activate the CD8+ T cell to differentiate into an effector cell. However, another model the 
”dynamic model of sequential two-cell interactions by APC”, introduced by Ridge et al. 
proposes that CD4+ T cells license the DC first by CD40-CD40L interaction. In a second step 
the “licensed” DC can efficiently activate CD8+ T cells [44]. 
Many groups have described that activation of DCs through CD40 to be crucial for inducing 
CTL responses [45]. Matzinger´s group demonstrated that activation of DCs in vitro by anti-
CD40 antibody can activate CTL responses in vivo in mice deficient in helper T cells [44]. 
However, this model was questioned when in 2002 Tanchot and colleagues published that 
CD40 expression is not crucial on APC but on CD8+ T cells. Activated CD4+ T cells express 
CD40L and peptide/MHC complexes and are able to induce CTL responses directly [46]. 
Interestingly, DCs can transfer costimulatory molecules and peptide/MHC complexes to 
CD4+ T cells and these CD4+ T cells can activate naïve CD8+ T cells in vitro and in vivo [47]. 
This transfer is TCR/MHC/peptide specific [48]. A study with different antigen secreting 
tumour cells revealed that only antigen bound to vesicles (exosomes) induced a strong CTL 
response and activated CD4+ T cells efficiently for delivering help for CD8+ T cells [49]. In 
vivo evidence showed that CD4+ T cell/CD8+ T cell/DC cell clusters are not important for 
CTL priming. The dynamic model rather suggest independent interactions between CD4+ T 
cells and APC and licensed APC with CD8+ T cell and subsequent activation of CD8+ T cells 
by CD4+ T cells [50]. 
CD8+ T cells are in general important cells in controlling infections of intracellular pathogens 
such as viruses. They recognize an infected cell by its expression of MHC/peptide complexes 
through the TCR. In tumours, CD8+ T cells recognize cells expressing aberrant peptides 
presented on MHC class I, which induces killing of the tumour cells either by 
perforin/granzymes or Fas/FasL induced apoptosis. Furthermore, they secrete IFNγ which 
induces upregulation of MHC class I on the target cells. Therefore, the potent induction of 
tumour-specific CD8+ T cells by cancer vaccines is of great interest and is an important part 
to control tumour growth.  
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1.1.4.1 Antibody-dependent cellular cytotoxicity  
Besides the induction of a strong CD8+ T cell response to eradicate tumour cells, a category 
of CD4+ T cells (T follicular helper cells) play a crucial role in stimulating B cells for 
production of high-affinity antibodies [51]. The interaction of CD40 on B cells and CD40L 
expressed on T cells is crucial for affinity maturation and isotype switching of antibodies as 
well as the formation of memory B cells [52]. Production of tumour-specific antibodies leads 
to specific recognition of tumour cells and to subsequent binding of NK cells, macrophages 
and neutrophils via Fc receptors. Thus, innate immune cells are activated and secrete 
cytotoxic granules containing perforin and granzymes to kill the tumour cell. This process is 
called antibody-dependent cellular cytotoxicity (ADCC). An important aim of cancer 
vaccines (e.g. DC-derived exosomes) is to enhance antibody production by B cells and 
further stimulate cytotoxic cells such as NK cells to induce ADCC. Interestingly, the 
activation of iNKT cells by αGC and the addition of TLR ligands enhanced ADCC mediated 
killing by NK cells in vitro [53]. A similar effect was seen by activating NK cells with IL-2 
and IL-21 [54, 55].  
 
1.1.5 Cancer Immunotherapy 
1.1.5.1 General overview of cancer immunotherapy 
The main goal of tumour immunology is to understand mechanisms involved in induction of 
anti-tumour immune responses and tumour rejection. Immunotherapy aims at initiating or 
augmenting an anti-tumour immune response to eradicate established tumours. Therefore, 
recognizing the tumour as “foreign”, identifying specific tumour-associated antigens (TAA) 
and potentiating antigen-presenting capacity are major goals of cancer immunotherapy.  
A weak physiological anti-tumour immune response can have different reasons. The immune 
system needs to recognize mutated “self” proteins. Normally T cells with high avidity 
towards self are deleted due to central and peripheral tolerance. Therefore, TAA-specific T 
cells are not very abundant in the tumour. In addition, there are no strong innate stimuli like 
pathogen-associated molecular patterns (PAMPs), which kick start the immune system and 
the antigen concentration can be very low. Also, the antigen concentration threshold for the 
activation of immunosuppressive regulatory T cells is much lower compared to naïve T cells 
which need 10 to 100 fold higher concentration, thus impeding anti-tumour responses [56]. 
Currently, two types of cancer immunotherapies have shown promising results during the last 
decades: immune-cell-targeted monoclonal antibody (mAb) therapy and adoptive cellular 
therapy (ACT). In the late 90s, different antibody-based targeted cancer therapies reached the 
market, a monoclonal anti-CD20 antibody for treatment of non-Hodgkin-lymphoma [57] and 
an antibody targeting Her2/neu in metastatic breast cancer [58]. In addition, the discovery of 
CTLA-4 and PD-1 [59, 60] resulted in the development of checkpoint blocking antibodies 
[61, 62]. mAb for targeting immune checkpoint molecules are not specific for a particular 
cancer type, but will influence the patient’s own immune system. Blocking of immune 
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regulatory molecules leads to more T cell activation and to a stronger anti-tumour immune 
response. Anti-CTLA-4 (ipilimumab) for treatment of metastatic melanoma has been 
approved by FDA in 2011 and anti-PD-1 (nivolumab) in 2014 for NSCLC [62] and 
melanoma [61]. Immune checkpoint blockage therapy can lead to tumour regression 
comparable with current cytotoxic chemotherapy treatments [63, 64]. Other promising results 
were shown by the transfer of ex vivo expanded tumour-infiltrating lymphocytes (TIL) or by 
chimeric antigen receptor (CAR) engineered T cells. CAR T cells express variable heavy and 
light chains of an antibody on their surface and are able to bind specific antigens. Upon 
binding, the T cell becomes activated and can kill the target cell. Second generation CAR T 
cells contain a costimulatory domain intracellularly for signal 2 and have shown up to 90% 
remission rates in advanced refractory B cell malignancies when targeting CD19, present on 
the B cell surface [65, 66]. However, treatment with CAR T cells requires known expression 
of a specific protein on the cell surface, which can be targeted. Thus, the investigation of 
specific protein signatures on cancer cells is of great need.  
Unfortunately, the efficacy of cancer vaccines, to induce a strong Th1 immune response and 
TAA-specific cytotoxic T cells to kill tumour cells, has been low. The list of approved 
adjuvants is very limited and many approved adjuvants such as alum induce a Th2 biased 
immune response [67]. Often specific CD8+ T cells get induced at the injection site (e.g. 
subcutaneous) but fail to migrate into the tumour (water in oil emulsion). Therefore, new 
approaches of vaccine design, delivery and adjuvant technology need to be developed and 
engineered. Besides using the best possible adjuvant for a cancer vaccine, the presence of the 
right peptides/proteins is crucial for inducing an anti-tumour immune response. Many studies 
focused on peptide-based cancer vaccines with poor therapeutic efficacy [68]. However, as 
mentioned above, many tumour antigens are unknown and specific T cells are rare due to 
thymic selection. The engagement of a broader set of T cells by immunization with different 
long peptides binding to MHC class I and II molecules have shown better results in certain 
clinical trials [69, 70]. An alternative approach can be the use of neoantigens, which arise 
during cancer progression. High mutation rates lead to higher frequencies of neoantigens and 
TILs [71]. The mutation rate between different tumours can vary, while melanoma and 
bladder cancer are malignancies with a high mutation rate, thyroid cancer and acute myeloid 
leukemia (AML) are the opposite [72]. Neoantigens can be analysed by biopsies and further 
bioinformatic analysis [73] and engineered into special designed personalized vaccines [74, 
75]. However, this is a very costly approach and beside the induction of tumour-specific T 
cells, immunoinhibitory effects in the tumour must be considered as well for effective cancer 
therapy. 
1.1.5.2 Nanoparticles as immune adjuvants 
Live attenuated viruses or inactivated pathogens are the most potent vaccines existing. 
However, the variation between different batches and side effects in immune compromised 
people can be a problem. Subunit vaccines consisting of only certain proteins are generally 
safer but unfortunately poorly immunogenic. Therefore, the understanding of nanoparticle-
based antigen delivery vehicles could improve current vaccine design for cancer therapy. 
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Currently, there are different nano- and microparticle-based delivery systems in development. 
Virus like particle (VLP)-based vaccines such as Gardasil (Merck) and Cervarix (Glaxo 
Smith Kline) against human papilloma virus (HPV) induced cervical cancer are already 
approved and on the market [76].  
The goal of a cancer vaccine is the induction of a broad spectrum of immune cells which, 
recognize and kill cancer cells. This includes activation of NK cells, NKT cells, CD8+ T cell 
and activation of B cells for the production of TAA-specific antibodies and finally the 
induction of long-lived helper T cells. DCs are the most crucial cells to elicit a strong primary 
immune response. DCs are phagocytic cells and the most potent antigen presenting cells in 
the immune system [23]. Antigen capture by immature DC and maturation through toll like 
receptors (TLR) activation induce upregulation of MHC and costimulatory molecules needed 
for T cell activation. The uptake of particles by DCs is dependent on size, shape, surface 
charge and interaction with surface receptors. Nano-sized particulate antigens have a large 
surface, which can expose charged molecules. This can enhance interaction with DCs and can 
therefore lead to better uptake of the antigen, efficient MHC loading and presentation to T 
cells [77]. 
Extracellular antigens are taken up by APC, processed in the endo-lysosomal compartment 
and presented on MHC class II molecules to activate CD4+ T cells as mentioned above. 
Presentation of extracellular antigens on MHC class I molecules follows a different 
processing pathway called cross-presentation, either through the cytosolic or the vacuolar 
pathway [27]. Different studies show accumulation of antigen in the cytosol, enhanced cross-
presentation and induction of CD8+ T cells after injection of engineered nanoparticles [78]. In 
addition, nanoparticles (< 200 nm) are superior in priming CD8+ T cells compared to 
microparticles (> 1 µm) and show better efficacy in inducing anti-tumour responses [79]. 
Interestingly, already in 1994 it was shown that macrophages take up antigen bound to latex 
beads and present it on MHC class I molecules 100 to 1000 times more efficiently compared 
to soluble antigens [80]. Particles with a diameter of 40 to 100 nm are efficiently taken up by 
DEC205+ DCs, however, larger particles predominantly bind to F4/80+ macrophages and 
could be taken up by phagocytosis or pinocytosis [79]. Furthermore, it has been reported that 
smaller sized particles (around 200 to 600 nm) induced a stronger cellular immune response 
compared to bigger particles (> 2 µm), which induced a better antibody response [81, 82]. 
Nanoparticles are inducing a more Th1 prone immune responses compared to microparticles, 
which favour a Th2 response [82, 83]. However, other authors claim that the particle size is 
not influencing the Th1/Th2 immune response [84]. The discrepancy of results may be due to 
different injection routes, particle composition and structure and different animal models used 
in the studies. Interestingly, also exosomal antigens have been shown to be cross-presented 
on APC in similar levels as antigen loaded VLP [85-87].  
Small particles subcutaneously injected passively drain to the draining lymph node, whereas 
larger particle from 500 to 1000 nm can be trapped at the injection site and need to be taken 
up by a DC to be transported to the lymph node [88]. Nanoparticles can carry native antigens 
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and bind directly to the B cells in the follicle. In addition, particulate antigens are also able to 
crosslink the BCR on B cells which leads to direct activation of antigen-specific B cells 
independently of T cell help [89]. A major advantage of using nanoparticles as vaccines is the 
possibility to engineer them to deliver several TLR ligands and antigens on the same particle. 
Recently, Mandraju and colleagues described that the combination of different TLR ligands 
enhance or inhibit CD8+ T cell activation; TLR3, TLR7 and TLR9 ligands are favouring 
CD8+ T cell induction [90]. CpG has been widely studied in cancer vaccines and shows a 
strong CD8+ T cell induction when loaded onto exosomes [91]. Exosomes engineered to carry 
different TLR ligands and certain antigens might be a perfect tool to target specific immune 
cells and to elicit a strong anti-tumour response. In conclusion, nanoparticle-based vaccines 
might mimic the nature and the structure of viruses and promote both humoral and cellular 
immune responses. 
 
1.2 INITIATION OF AN IMMUNE RESPONSE IN THE SPLEEN 
The spleen is the essential organ for capturing blood-borne antigens. The blood passes 
through the spleen with a low flow rate enabling many specific immune cells to capture 
antigens from the blood directly and to induce an immune response. The blood is entering the 
spleen through the central arterioles and flows through the marginal sinus where the antigens 
can be captured and transferred to the B cell follicles. Marginal zone metallophilic 
macrophages (MMM) are located at the inner site of the marginal sinus, close to the white 
pulp. Marginal zone macrophages (MZM) on the other hand are located at the outer site of 
the sinus. Both macrophage types express different pattern recognition receptors (PRR) like 
scavenger receptors or C-type lectin receptors to capture antigens [92]. In addition, DCs in 
the circulation can capture antigens and transport them directly to the marginal sinus. CD169 
(Siglec-1) expressing MMM are found in the B cell zone after LPS stimulation [93], which 
indicates that they might play a role in antigen transfer from the marginal zone to the B cell 
area. Furthermore, antigens bound to CD169+ MMM are transferred to CD8+ DCs leading to 
cross-presentation and subsequently to the activation of CD8+ T cells [94]. CD8+ DCs are 
located in the T cell zone and outer marginal zone, CD8- DCs can be found in the red pulp 
and marginal zone. However, CD8+ and CD8- DCs capture similar amounts of soluble 
antigen or antigen coated beads, but only CD8+ DC are able to cross-present these antigens 
[95]. Therefore, CD8+ DCs need a specialized machinery for cross-presentation [96]. 
Interestingly, CD8+ DCs express a specific set of proteins involved in MHC class I 
presentation including TAP1 and TAP2. In contrast, CD8- DCs express proteins involved in 
MHC class II presentation [97]. DCs can also take up antigens via FcγRIIB, which leads to 
the access of a non-degradable pathway in DCs and to recycling of the native antigen on the 
cell surface and subsequent activation of B cells via the BCR [98]. 
Marginal zone B cells (MZB) are located in the outer layer of the marginal sinus and express 
sphingosine-1-phosphate (S1P) receptors 1/3, which bind S1P from the blood. This signal 
retains the MZB cells in the marginal zone and interferes with the strong attraction signal 
towards the follicle expressed by follicular dendritic cells (FDC). In addition, MZB cells 
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interact with stromal cells through the expression of integrins (αLβ2 or LFA1) with ICAM 
and VCAM on stromal cells to retain the MZB cell. MZB express poly-reactive BCRs, which 
recognize different microbiological patterns and clear bacteria from the blood. Binding of 
blood-borne microorganisms to the BCR of the MZB and simultaneous engagement of TLR 
leads to the production of low affinity antibodies [99]. This T cell independent pathway for 
the production of low-affinity IgM antibodies is important for the first line of defence until 
follicular B cells take over with the production of high-affinity antibodies. As mentioned 
above, MZB could also encounter antigens from MMM or MZM or from DC and neutrophils 
captured in the periphery. DCs provide survival signals to MZB through the expression of 
BAFF and APRIL [100] by binding to the transmembrane activator and CAML interactor 
(TACI) on MZB. This induces a signal to MZB for class switch recombination and antibody 
production.  
Upon binding of antigens to MZB by complement receptors CD21 or CD35, MZB 
downregulate S1P receptors and upregulate the chemokine receptor CXCR5. Thus, they 
migrate to the follicle and can deposit the antigen on the FDC, subsequently they 
downregulate the chemokine receptor and can migrate back to the marginal zone. On the 
other hand, MZB can migrate to the PALS, where they initiate a germinal center (GC) 
response by binding to cognate CD4+ T follicular helper cells (Tfh), which have been 
activated by DCs. The antigen on the FDC leads to selection of high affinity germinal center 
B cells through somatic hypermutation. The interaction of GC B cells with Tfh cells through 
CD40-CD40L and MHC-TCR binding, leads to the development to plasma cells and long 
lived memory cells with high-affinity IgG production.  
 
1.3 NKT CELLS 
1.3.1 General Overview 
Natural Killer T (NKT) cells are bridging the innate and adaptive immune system and express 
receptors which are characteristic for NK cells and T cells. They recognize glycolipid 
antigens by a restricted set of TCR presented by the non-classical MHC class I like molecule 
CD1d [101]. Compared to MHC class I molecules, which are expressed by all nucleated 
cells, CD1d is only expressed by DCs, macrophages and B cells, at high levels by marginal 
zone B cells [102]. NKT cells express the NK cell marker NK1.1 in mice and a restricted set 
of TCRα (mice Vα14-Jα18, humans Vα24-Jα18) and TCRβ (Vβ8, Vβ7, Vβ2 in mice, Vβ11 I 
humans) chains. This goes in line with the fact that Vα14 TCR transgenic mice have higher 
percentage of NKT cells [103] and Jα18-/- mice lack NKT cells completely [104]. NKT cells 
also express T cell markers such as CD25, CD44 and CD69 and the majority is CD4+, only a 
small subset of human NKT cells expresses the CD8α chain. They are very abundant in mice 
and represent around 0.5% of the T cell population in blood and lymph nodes, 2.5% in spleen 
and approximately 30% in the liver. However, the frequency in humans is around 10% 
reduced in all organs, but can differ up to 100 times between different individuals. NKT cell 
are sub-classed into Type I and II NKT cells. Type I NKT cells (iNKT) are defined to 
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recognize α-galactosylceramide (αGC), whereas type II NKT cells recognize sulfatide 
presented by CD1d. Type II NKT cells express a more diverse set of TCRα chains compared 
to type I NKT cells. 
The first and best described glycolipid found to stimulate NKT cells was αGC, isolated from 
a marine sponge [105]. αGC shows a strong affinity for CD1d in mice and humans. NKT 
cells produce a wide range of cytokines upon αGC stimulation. Already 1-2 hours after 
stimulation they produce Th1 cytokines such as TNF and IFNγ and Th2 cytokines such as IL-
4 and IL-13. The regulation of Th1/Th2 cytokine expression is only partly understood. In 
mice, the rapid cytokine production is due to the presence of pre-formed mRNA stored in the 
cell, which enables a rapid response upon activation [106]. Injection of soluble αGC leads to 
a rapid production of IL-4, which is followed by a long lasting production of IFNγ and 
upregulation of CD40L on NKT cells. The majority of research has been focusing on IFNγ 
and IL-4 secretion, however, the picture is much broader and NKT cells have also been 
described to produce GM-CSF, TNF, IL-5, IL-10, IL-13, IL-17 as well as IL-21 [107, 108]. 
CD40-CD40L crosslinking results in upregulation of CD80/CD86 on DCs and IL-12 
production, which in turn is critical to enhance the activation of NKT cells and their IFNγ 
expression [109]. Interestingly, NK cell mediated killing was also enhanced shortly after αGC 
engagement due to IFNγ release by NKT cells [110]. However, activation of NKT cells 
through αGC leads to downregulation of their TCR, to massive apoptosis approximately 3 to 
4 days after exposure and to long lasting unresponsiveness [111, 112]. Interestingly, injection 
of αGC-loaded DCs induced a prolonged IFNγ response and was more potent in reducing 
metastasis in a B16 melanoma model compared to soluble αGC alone [113]. This suggests 
that αGC bound to DCs is more potent than soluble αGC in tumour therapy.  
Apart from recognizing αGC, NKT cells are important in inducing immunity against bacteria 
like Sphingomonas. They recognize microbial α-glycuronylceramides, which can be found in 
gram-negative and lipopolysaccharide negative bacteria [114]. In mice and humans different 
self-ligands have also been described, however, the physiological role for these ligands 
remains unclear. Isoglobotrihexosylceramide (iGb3), a glycosphingolipid, was described to 
bind CD1d and activate NKT cells [115]. However, later on, its importance was questioned 
by showing that mice lacking iGB3 synthase develop a normal population of NKT cells 
[116]. In 2011 the endogenous ligand β-D-glucopyranosylceramide (β-GlcCer) was described 
to accumulate after TLR stimulation and to translate an innate TLR signal into an activation 
signal for iNKT cells [117]. NKT cells can function as an enhancer for the immune response 
and activate different immune cells by expression of different cytokines. This makes them a 
well suited target for cancer immunotherapy.  
 
1.3.2 Anti-tumour Function of iNKT Cells 
NKT cells play an important role in anti-tumour immunity as well as in immune surveillance, 
and mice lacking NKT cells are more susceptible to MCA-induced sarcomas and B16 
melanomas [8, 118]. Interestingly, this effect was dependent on IFNγ expression by NKT 
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cells and independent of perforin. The anti-tumour effect mediated by αGC is highly 
dependent on IFNγ production by NK and NKT cells [119], which leads to activation of DCs 
and to subsequent IL-12 production. This can augment the adaptive immune response by 
activating cytotoxic CD8+ T cells and helper CD4+ T cells [120, 121]. NKT cells do not only 
mediate anti-tumour effects through activation of other immune cells, they can also directly 
target and kill CD1d-bearing tumour cells through similar mechanisms as used by NK cells 
and CD8+ T cells such as perforin [122], TRAIL [123] or Fas ligand [124]. In addition, 
human tumours have been shown to express specifically glycosylated gangliosides [125], 
which are natural ligands for CD1d and can be presented on B cells to activate NKT cells 
[126]. Many tumour cells downregulate the expression of CD1d and are invisible for NKT 
cell mediated killing, which can lead to enhanced metastasis due to reduced control 
mechanisms in the primary tumour [127]. However, IFNγ dependent activation of other 
immune cells is still functional. Interestingly, type I and II NKT cells can have different 
functions in the tumour, while NKT I cells can have a protective role, NKT II cells can be 
immunosuppressive and secrete anti-inflammatory cytokines [128].  
 
1.3.3 Immune Regulatory Type II NKT Cells in Cancer 
There is also evidence that NKT cells can negatively influence anti-tumour immune 
responses. In certain tumour models NKT cells produce IL-13, which in turn activates 
myeloid (GR1+ CD11b+) cells to produce TGFβ that inhibits CTL function [129, 130]. In 
addition, CT26 colon carcinoma metastasis in the lung was greatly reduced in CD1d-/- mice. 
The effect was dependent on CD8+ but not on CD4+ T cells [131]. In summary, certain 
subsets of NKT cells can induce immunoinhibitory effects by producing IL-13. Further 
studies showed that type II NKT cells are sufficient for downregulating immune surveillance 
[132] and that injection of sulfatide, a type II NKT cell ligand, leads to higher metastatic 
burden in a CT26 colon carcinoma model [133]. Therefore, the understanding of NKT cell 
subsets and their activating and regulatory ligands is of major importance for developing new 
cancer therapies.  
 
1.3.4 NKT cells in Cancer Immunotherapy 
Promising results in many tumour models in mice led to several clinical trials using αGC in 
cancer patients. Intravenous injection of αGC in cancer patients did not induce significant 
biological effects. Only in patients with high NKT cell frequencies the production of 
cytokines was detected [134]. Injecting αGC-loaded DC led to better NKT cell activation and 
improved tumour control in mice [113]. However, several phase I clinical trials with this 
approach showed wide variation due to differences in NKT cell frequencies in the patients. 
Co-administration of NKT cells and αGC-pulsed DC induced significant anti-tumour 
immunity [135]. Furthermore, many cancer patients have impaired NKT cells, they fail to 
proliferate ex vivo [136] or are skewed towards a Th2 cytokine production [137], which 
challenges NKT cell-based therapies.  
 14 
1.4 EXTRACELLULAR VESICLES 
1.4.1 Exosomes 
1.4.1.1 General overview 
All cells investigated until today release small vesicles, which have important physiological 
functions and can be found in body fluids like plasma, urine, breast milk or saliva [138-140]. 
These vesicles differ in size, cellular origin and molecular composition. Extracellular vesicles 
carry important cargo and can transfer proteins, lipids and RNA to other cells [141, 142]. 
Intercellular communication is an important mechanism in all organisms and can be mediated 
by either small molecules such as hormones, growth factors or cytokines and act directly on 
the releasing cell (autocrine) or on other cells (endocrine). Direct cell to cell contact in 
proximity is mediated by desmosomes, tight junctions and gap junctions. A mechanism 
which has been overlooked is the intercellular communication via extracellular vesicles like 
exosomes and microvesicles.  
Extracellular vesicles elicit important biological functions and act as messengers in immune 
activation and regulation in different malignancies. On one hand they can drive inflammation 
and act as immune activators; on the other hand tumour-derived vesicles downregulate the 
immune system through immune-suppressive molecules and can transfer pro-metastatic 
proteins to distant sites and facilitate metastasis [142, 143]. Thus, extracellular vesicles 
became a focus of interest for their use as therapeutic agents, as biomarkers or as a target for 
future cancer therapies.  
The term exosomes was first used in 1981 when the group of Trams showed that extracellular 
vesicles are associated with adenosine production [144]. The first breakthrough paper was 
published by Johnstone and colleagues in 1987 where they extensively described the 
characteristics of exosomes. They showed that the transferrin receptor is lost during 
reticulocyte to erythrocyte maturation and is released via exosomes into the extracellular 
space [145]. In 1996, it was shown that B lymphocyte-derived vesicles carry MHC molecules 
and were able to stimulate cognate T lymphocytes [146]. This finding raised the interest for 
using exosomes in cancer therapy. Later on, the discovery of tumour-derived exosomes 
opened up a new field of research and scientists were interested in their role in cancer 
metastasis and tumour microenvironment and their use as biomarkers.  
Extracellular vesicles are a heterogeneous group and differ in size, lipid and protein 
composition. Today three main subgroups of extracellular vesicles have been described: i) 
apoptotic bodies, ii) microvesicles/ectosomes and iii) exosomes. Apoptotic bodies are 
released during cell death during which cytosol and organelles are packed into the blebbing 
plasma membrane [147]. They have a wide size range and may contaminate other vesicle 
pellets. Microvesicles are released directly from the surface of the cell while exosomes have 
endosomal origin. Microvesicles and exosomes can be clearly distinct from apoptotic bodies 
by their proteomic profiles [148].  
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Figure 2: Size distribution of extracellular vesicles in comparison to bacteria, viruses and eukaryotic 
cells 
 
1.4.1.2 Definition 
Exosomes are extracellular vesicles with endosomal origin with an approximate diameter of 
30 to 150 nm and are released by all kind of cells investigated until this day. Due to their 
endosomal origin they do not express mitochondrial or endoplasmatic reticulum (ER)-derived 
proteins. They carry proteins, lipids and nucleic acids and can transfer information from one 
cell to the other. Exosome are usually isolated using different centrifugation and filtration 
steps with a final ultracentrifugation step at 100´000 x g. Microvesicles on the other hand 
pellet at 10´000 x g. More recently, exosomes and microvesicles are also isolated by size 
exclusion chromatography. Visualization by transmission electron microscopy (TEM) reveals 
exosomes with a cup-shaped morphology, which might be due to fixation and embedding 
methods. Exosomes without any fixation show a round morphology. Flotation on a sucrose 
gradient defined them at a density level of 1.13 to 1.19 g/ml. Currently, there is still no 
specific marker for exosomes. Therefore, vesicles are best characterized by different methods 
such as western blot, electron microscopy, FACS and nanoparticle tracking analysis. 
Selection of subpopulations of exosomes can be achieved by different methods such as 
immune-affinity purification [149, 150], isoelectric gradients [151], size based methods [152] 
and the classical sucrose gradient. Interestingly, subpopulations isolated by sucrose gradients 
have distinct proteomic and genomic profiles and are involved in different pathways [153]. 
However, subpopulation can vary depending on the isolation technique and cell of origin. In 
general, proteins enriched in exosomes and considered as exosomal markers include 
tetraspanins (CD9, CD63 and CD81), MHC class I and II molecules, heat shock proteins 
(HSP70, HSP90) [154, 155] and proteins from the endosomal sorting complex required for 
transport (ESCRT) components such as TSG101 and Alix [156] (Figure 3). Furthermore, 
exosomes can also contain cytoskeletal proteins such as actin and tubulin [157]. However, 
tetraspanins have also been shown to be associated with apoptotic bodies and microvesicles 
[158] and only a subpopulation of exosomes may contain CD63 and Tsg101 [159, 160]. In 
addition, several proteins used as exosomal markers can also be expressed in larger vesicles 
pelleting at lower speeds, this includes flotillin, heat shock proteins or MHC class I and II 
molecules. Lately, syntenin-1, Tsg101, ADAM10, EHD4 and Annexin XI have been 
described to be a better marker for exosomes compared to CD9 and CD63 [160].  
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Exosomes express a specific set of glycoproteins, which is different from the glycol pattern of 
the mother cell [161] and interestingly also from apoptotic bodies [162]. The glycosylation 
pattern of exosomes can vary depending on physiological conditions and might have an 
important function in targeting other cells or in systemic biodistribution [162, 163]. Beside a 
specific glycol-pattern, exosomes are enriched in certain lipids such as sphingomyelin, 
cholesterol and phosphatidylserine compared to the parent cell [164]. They can also express 
ceramide [165], flotillin and phosphatidylethanolamine, which leads to a more rigid 
membrane and contributes to their stability in the extracellular environment [166]. 
 
 
Figure 3: Protein components of exosomes A) DC-derived exosomes express costimulatory and 
adhesion molecules and CD1d, B) Tumour-derived exosomes express immunoinhibitory molecules, 
oncoproteins and enzymes promoting tumour progression. 
 
Exosomes contain intact RNA with a size range of up to 700 nucleotides (nt), while cellular 
RNA can be 400 to 12 000 nt long [167]. They may contain mRNA and mRNA fragments 
[141], miRNA [168] and short DNA sequences [169]. Several studies report absence of 18S 
and 28S ribosomal RNA (rRNA) [158, 170], however, depending on the isolation protocol 
certain publications describe the presence of rRNA in exosomes [153, 171]. Furthermore, 
microvesicles (here used as another name for exosomes) were described to contain mainly 
ssDNA [172]. Variability between studies exists and depending on methodology, isolation 
protocol and purity of the isolated vesicles results might differ. Interestingly, the RNA 
content of exosomes does not resemble the RNA content of the parent cell. Some RNA 
species are enriched in exosomes [141, 142, 170] and a specific sequence motif has been 
described, which induces loading of the microRNA into exosomes [173]. This indicates a 
selective and active process for RNA loading into exosomes. Heterogeneous nuclear 
ribonucleoprotein A2B1 (hnRNPA2b1) binds specifically the sequence motives and sorts 
miRNA into exosomes, mutagenesis of these motifs changes the loading of miRNA into 
exosomes [173]. miRNA content can differ between MV and exosomes and in different 
exosomal subpopulations [174]. Remarkably, exosomes can transfer RNA between different 
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cells in vitro with translation of the protein in the recipient cells [141, 142]. Therefore, 
exosomes might function as communication vesicles and transfer RNA, which is protected in 
the exosome lumen from degradation by RNase. In contrast, RNA can also be associated with 
RNA-binding proteins (Argonaut-2, Ago2) [175] or lipoproteins [176] to prevent their 
degradation. Certain mRNA species were exclusively associated with vesicles or protein 
complexes but the majority of RNA was associated with RNA-binding proteins and not 
vesicles [175]. However, it is still not clear how cells take up miRNA associated to Ago2. 
The association to protein complexes, lipoproteins or vesicles might greatly affect the 
biological function and uptake by other cells.  
1.4.1.3 Exosome Biogenesis 
During maturation of an early to a late endosome, intra luminal vesicles (ILV) are budding 
off from the membrane into the endosome lumen leading to the formation of multivesicular 
bodies (MVB). MVB either fuse with the lysosome, where all the content is degraded by 
hydrolases, or with the plasma membrane (Figure 4). The lipid content of an MVB fusing 
with a lysosome is significantly different to an MVB fusing with the plasma membrane [177] 
and cholesterol-poor MVB are normally degraded in lysosomes [178]. Once the MVB has 
fused with the plasma membrane, the ILVs are released into the extracellular space and are 
now called exosomes. There are several different mechanisms for the formation of MVB, the 
best described and investigated is dependent on the endosomal sorting complex required for 
transport (ESCRT). Apart from the ESCRT machinery, tetraspanins and lipids also play 
major roles in exosomes biogenesis.  
The ESCRT complex consists of four different subunits, ESCRT-0, -I, -II, and –III. ESCRT-0 
is important in binding mono-ubiquitinated cargo proteins and binds via Hrs to TSG101 of 
ESCRT-I. Silencing of Hrs in mammalian cells leads to a reduced formation of ILVs [179]. 
ESCRT-I and II are responsible for the membrane deformation process and for the shipment 
of the cargo into the vesicles. ESCRT-I recruits ESCRT-II and finally ESCRT-II binds 
ESCRT-III. The dissociation of the vesicle is mediated by AAA ATPase Vps4. A study 
silencing multiple components of the ESCRT complexes showed epidermal-growth factor 
(EGF)-independent formation of MVB [180]. Thus, there must be other molecules involved 
in ILV budding. Recently, it has been shown that depletion of Hrs induces a CD63 dependent 
formation of ILVs in HeLa cells [181]. Cells deficient of four subunits of the ESCRT 
machinery can still produce CD63 positive MVB. Apart from CD63 and ESCRT dependent 
formation of ILV, lipid induced budding has been described as well. The sphingolipid 
ceramide has been shown to be important for ILV formation in mouse oligodendroglia cells 
[165]. Blocking of neutral sphingomyelinases enzyme (snMase) (which is important for 
ceramide synthesis) reduced exosome formation. In contrast, the impairment of snMase does 
not inhibit the formation of MVB in human melanocytes. Different cell lines can use different 
mechanisms for exosome formation. Furthermore, other lipids like cholesterol and 
lysobisphosphatidic acid (LBPA) and phosphatidic acid have been suggested to be involved 
in exosome biogenesis [182-184]. 
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Figure 4: Exosomes are 
formed as intraluminal vesicles 
(ILV) in the late endosomes 
resulting in multivesicular 
bodies. Upon fusion with the 
cell membrane, ILVs are 
released into the extracellular 
space, and are then called 
exosomes. In contrast, 
microvesicles bud off directly 
from the cell plasma 
membrane. 
 
1.4.1.4 Exosome secretion 
Rab GTPases are important proteins involved in membrane trafficking, vesicle transport and 
membrane fusion. Many studies have investigated the involvement of Rab proteins in 
exosome secretion. Already in 2002 it was shown that secretion of exosomes by 
erythroleukemia cell line K562 is modulated by Rab11 [185]. In 2010 Rab27 and Rab35 were 
identified to play an important role in exosome secretion. Inhibition of Rab35 in a murine 
oligodendroglia cell line led to accumulation of ILVs and to a reduced exosome secretion 
[186]. Ostrovski and colleagues found that Rab27 isoforms effect exosome secretion in HeLa 
cells and shRNA induced silencing of Rab27a/b led to a reduced exosome release [187]. 
However, Rab27a silencing in 4T1 cells leads to reduced expression of CD63, Tsg101, Alix 
and Hsc70 on released vesicles but not of CD9 and MFGE8. Interestingly, CD9 and MFGE8 
can also be found on microvesicles, pelleted at 10´000 x g. The authors propose that the 
100´000 x g exosome pellet is a mixture of vesicles with different cellular origin [188]. 
Several Rab proteins have been shown to be important in cancer progression and metastasis. 
For example, gastric cancer patients have a lower survival rate when expressing high levels of 
Rab40b. [189] Recently, two studies correlated expression levels of different Rab proteins in 
cancer tissue with clinical status of these patients. In pancreatic cancer patients the expression 
level of Rab27a in the cancerous tissue is associated with tumour stage and vascular invasion 
[190]. The upregulated expression of Rab proteins in cancer patients might induce an 
enhanced exosome secretion from the cancer cells, which in turn promotes cancer invasion 
and progression.  
 
1.4.2 Microvesicles 
Microvesicles (MV) were first described in shedding from activated erythrocytes and 
platelets [191] and were shown to be important in coagulation [192]. MVs are shed directly 
from the plasma membrane after a process of protein and lipid rearrangement. Like 
exosomes, MVs are shed from a variety of cell types and can be found in body fluids like 
urine, plasma and ascites [193-195].  
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Changes in the activation status of a cell and subsequent calcium accumulation in the cytosol 
lead to rearrangement of the lipid membrane and to exposure of phosphatidylserine to the 
external lipid layer. The asymmetry of the cell membrane and disruption of the cytoskeleton 
induces membrane budding [193]. There are no specific proteins which have been described 
to be a marker for MVs. Certain proteins were described to be part of the budding process. 
ARF6, a GTP binding protein, has been shown to be involved in membrane budding and MV 
release in tumour cells [196]. In addition, certain studies show that MV budding can be 
mediated by Tsg101 and Vps4 (part of the ESCRT machinery), which have previously been 
described to mediate exosome biogenesis [197]. Interestingly, proteins from the ESCRT-0 
complex are often not involved in plasma membrane budding [198], therefore the presence of 
ESCRT-0 supports the MVB origin of the vesicle. As already discussed for exosomes, 
ceramide and tetraspanins are also important for the MV budding process. Ceramide also 
accumulates in the membrane of MV and acid sphingomyelinase is important for the budding 
process [199]. In addition, tetraspanins can form special microdomains in the plasma 
membrane, which enables MV budding [158]. MV have been shown to express an 
overlapping but distinct different protein profile compared to exosomes [153] (Table 1).  
 
Table 1: Overview on exosomes and microvesicles 
 Exosomes Microvesicles 
Size 30 – 150 nm 100 – 1000 nm 
Other name TEX, DEX, tolerosomes, prostasomes ectosomes, microparticles 
Molecular composition/Markers Flotillin, Alix, Tsg101, tetraspanins 
(CD9, CD63, CD81) 
Tissue factor, flotillin, parts of the 
ESCRT complex 
Sedimentation 100´000 x g 10´000 – 20´000 x g 
Lipid composition cholesterol sphingomyelins,  
phosphatidylcholine, 
phosphatidylethanolamine [166] 
ceramide 
Similar to plasma membrane, 
aminophospholipids, phosphatidyl-
serine and -ethanolamine, in outer 
leaflet [200] 
Nucleic acids mRNA, miRNA, small RNA rRNA [158] 
Origin Late endosome, MVB Plasma membrane 
Assembly/budding process ESCRT, CD63, ceramide dependent 
[165]  
TSG101, ARRDC1- mediated [201] 
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1.5 EXOSOMES IN THE IMMUNE SYSTEM 
1.5.1 Exosomes in Immune Activation 
The first time exosomes drew interest in the immunological society was in 1996 when 
antigen-presenting cells were described to secrete vesicles expressing MHC class II 
molecules. Raposo and colleagues showed that exosomes from Epstein-Barr Virus 
transformed B cells express MHC/peptide complexes, costimulatory and adhesion molecules 
and can directly stimulate proliferation of a cognate CD4+ T cell line [146]. This was the first 
evidence that exosomes from immune cells might play an important role in cell to cell 
communication in the immune system and that extracellular vesicles are sufficient to activate 
T cells in vitro. At the same time different research groups became interested in DCs loaded 
with acid eluted tumour peptides as cancer therapy. Exosomes from mature bone-marrow 
derived dendritic cells (BMDC) pulsed with acid eluted tumour peptides primed tumour-
specific CD8+ T cells in a mouse tumour model, which led to eradication of established 
tumours. Furthermore, the induction of a tumour-specific CTL response was fully dependent 
on syngeneic MHC/peptide complex on exosomes and no effect was seen after injection of 
allogeneic exosomes [202]. However, in another system exosomes from BMDC indirectly 
loaded with the major CD8+ T cell peptide SIINFEKL were unable to induce antigen-specific 
T cells in vivo. Interestingly, only whole OVA antigen-loaded exosomes induced antigen-
specific CD8+ T cells. This effect was dependent on the presence of CD4+ T cells and 
partially on marginal zone B cells [203]. These results were supported by a recently published 
study where peptide-loaded B cell-derived exosomes were weak in inducing antigen-specific 
CD8+ T cell responses [163]. 
Mature DC-derived exosomes express high levels of MHC class I and II molecules, CD54 
(ICAM-1) and the costimulatory molecules CD80 and CD86. Hence, they can possibly 
activate CD4+ and CD8+ T cell responses. Exosomes form mature DC are much more 
efficient in activating and inducing T cell responses compared to exosomes from immature 
DCs, which express lower levels of MHC and costimulatory molecules [204, 205]. DC-
derived exosomes can activate T cell clones, cell lines and primed CD4+ and CD8+ T cells 
directly [139, 146, 206]. However, certain studies showed that the exosome-induced T cell 
activation was minor and a strong T cell response could only be induced in the presence of 
DCs [207, 208]. This might be an explanation for the poor ability of DC-derived exosomes to 
stimulate naïve T cells, where the threshold for activation is much higher compared to T cell 
clones and memory T cells [209]. Furthermore, the small size of exosomes and the low 
amounts of MHC/peptide complexes on exosomes can also be a limiting effect for their 
stimulatory capacity. Hsu and colleagues showed that exosomes, which are directly loaded 
with peptide in mildly acid conditions, were more effective in inducing T cell proliferation 
compared to indirectly loaded exosomes in vitro. This augments the numbers of MHC 
molecules loaded with peptides significantly [210]. In conclusion, for the activation of naïve 
T cells the uptake and processing by DC is likely necessary [209].  
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1.5.1.1 Exosome binding and uptake 
The immunogenicity and uptake of exosomes likely depends on certain molecules expressed 
on the exosome surface. Expression of ICAM-1 increases exosomal immunogenicity in vitro 
[205]. Vesicles released by Drosophila cells engineered to express MHC/peptide complexes 
and ICAM-1 shown to bind to cognate T cells efficiently and activated them in the presence 
of CD80/CD86 [211]. The presence of ICAM-1 on exosomes might influence the binding of 
exosomes to T cells and is crucial for T cell stimulation. Mature DC-derived exosomes 
contain high levels of ICAM-1 and can efficiently bind to LFA-1 expressed at high levels by 
on T cells, macrophages, B cells and CD8+ DCs. T cells can be the target of MHC class II 
expressing DC-derived exosomes [212] Interestingly, only activated T cells (through 
CD3/CD28) can recruit DC-derived exosomes via ICAM-1/LFA-1 interaction. DC-derived 
exosomes can bind to T cells during a cognate DC-T cell interaction [206]. Furthermore, DC-
derived exosomes can also interact directly with DC through expression of ICAM-1 on 
exosomes and LFA-1 on DC. LFA-1-/- DCs do not interact with exosomes and cannot induce 
T cell responses [205, 213].  
The interaction of exosomes with immune cells in lymphoid organs like spleen and lymph 
nodes is crucial for the induction of an exosomal induced immune response. Capturing of 
intravenously injected exosomes in the spleen is mediated by MOMA+ macrophages, ER-
TR9 macrophages and CD11c+ DCs of the marginal zone. They can transfer exosomal 
proteins directly to the follicle [87]. Similarly, already 5 min after injection Siglec-1 (CD169) 
expressing macrophages in the marginal zone and in the subcapsular sinus of lymph nodes 
capture B cell-derived exosomes, which are enriched in α-2,3-linked sialic acid. Interestingly, 
depletion of CD169 led to binding to SIGNR1+ macrophages and F4/80+ red pulp 
macrophages [163]. Just recently, CD169+ macrophages were shown to play an important 
role in clearing tumour-derived extracellular vesicles and blocking their dissemination and 
metastasis [214]. Other studies describe CD8+ DCs to be important for exosome uptake 
compared to CD8- DCs and plasmacytoid DCs. Already 24 hours after i.v. injection BMDC-
derived exosomes were found in the T cell zone in the spleen and on follicular DCs [215, 
216].  
Exosomes also express milk-fat globule E8 (MFG-E8; known as lactadherin) and 
phosphatidylserine (PS). Both can act as opsonins and enhance phagocytosis and uptake. PS 
is normally only expressed on the outer plasma membrane leaflet during apoptosis. MFG-E8 
can interact directly with PS but also contains an integrin binding domain for cell interaction. 
Blocking of PS and RGD sequences (e.g. MFG-E8) reduces uptake of exosomes by DCs 
[87]. Furthermore, exosomes have been shown to bind the C-type lectin receptor DEC205 on 
DCs [217], which is highly expressed on marginal zone macrophages to capture blood-borne 
antigens. Antigen targeting to DEC205 leads to enhanced uptake and cross-presentation and 
to more efficient priming of the immune system [218]. Thus, binding of exosomes to 
DEC205 on DCs might induce cross-presentation and activation of CD8+ T cells.  
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Uptake of exosomes by DCs is an active process and can be reduced by adding cytochalasin 
D which interrupts actin polymerization or by incubation at 4 °C. In addition, blocking of 
tetraspanins CD9 and CD81 also reduced uptake of exosomes by DCs [87]. Once exosomes 
are taken up by DCs, the MHC/peptide complex can be degraded or reused on the DC surface 
for T cell simulation. The transfer of exosomal MHC/peptide complexes to MHC class 
I/MHC class II deficient mature DC have been shown to induce T cell proliferation by 
recycling the exosomal MHC/peptide complex [208, 209]. Furthermore, exosomes can 
transfer HLA-A2/MART1 peptide complex to APC lacking the HLA-A2 molecule [210]. In 
conclusion, DCs and macrophages play a crucial role in initiating exosome induced immune 
responses in lymphoid organs and capture exosomes through specific surface receptors. 
 
1.5.2 Immunomodulatory Exosomes in Cancer Therapy 
As described above, exosomes can potently stimulate the immune system. Here follows an 
overview of reports where either tumour-derived or DC-derived exosomes have been used in 
preclinical cancer models (Table 2) and clinical trials (Table 3). In some cases, DC-derived 
exosomes were loaded with tumour peptides or whole antigens to elicit a specific anti-tumour 
response [202, 219]. Several studies potentiated the immune response by adding innate 
stimuli [220-222]. On the other hand tumour-derived exosomes were used as antigen source 
in several vaccination models [223-225] and in some cases the immunogenicity of TEX was 
enhanced by different methods [154, 226-229]. In summary, in vivo effects are well described 
in preclinical models; unfortunately, the efficiency is very low in the clinical trials.  
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Table 2: Summary of results of exosome-based therapies in preclinical models 
Cancer type Exosome vaccine Injection route Outcome Ref.  
Mastocytoma, 
mammary 
carcinoma  
Mature BMDC-derived 
exosomes, loaded with acid 
eluted cancer peptides 
therapeutic model 
i.d. 3-5 µg T cell dependent 
eradication of established 
tumours 
[202] 
Plasmacytoma 
J558  
Tumour cell derived exosomes 
vaccine model 
s.c. 2,5-5 µg T cell dependent 
immunity against 
plasmacytoma  
[223] 
Colon carcinoma 
CT26  
 
 
MUC1 transfected cell lines, 
CT26 murine colon carcinoma 
and TA3HA mammary 
carcinoma 
vaccine model 
i.d. 4 or 20 µg, 
with Incomplete 
Freund´s Adjuvant 
MUC1 carrying 
exosomes from CT26 and 
TA3HA induced anti-
tumour effects 
[224] 
SW480 human 
colon adeno-
carcinoma in nude 
mice 
exosomes from heat-stressed 
(HS) carcino-embryonic 
antigen (CEA) positive tumour 
cells  
therapeutic model 
s.c. 5 µg higher CTL induction 
after injection of 
exosomes from HS 
tumour cell, better 
survival after adoptive 
transfer of splenocytes of 
HS-exosome injected 
mice in a SW480 tumour 
model  
[226] 
B16F10 melanoma 
co-expressing 
HLA-A2/gp100 
BMDC-derived exosomes, 
MelanA/Mart1/gp100 peptides 
and CpG/ODN in combination 
with cyclophosphamide (CTX) 
treatment model 
10 µg foodpad enhanced CTL response 
and survival in a B16F10 
tumour model 
[220] 
L1210 murine B 
lymphocytic 
leukemia 
Tumour cell line-derived 
exosomes 
vaccine model 
s.c. 2.5 or 5 µg Prolonged survival of the 
exosome vaccinated 
groups 
[225] 
BL6-10OVA tumour  BMD- derived exosomes 
loaded with OVA or EG7 
derived exosomes 
vaccination model 
i.v. 10 µg BMDC exosomes 
induced more antigen-
specific CD8+ T cells and 
less metastasis compared 
to tumour derived 
exosome  
[230] 
EG7 lymphoma EG7-derived exosomes with 
bound staphylococcal 
enterotoxin A (SEA) 
vaccination model 
s.c. 10 µg Induction of more 
antigen-specific T cells 
and longer survival after 
injection of EG7-SEA 
exosomes 
[227] 
L1210 murine B 
lymphocytic 
leukemia 
BMDC-derived exosomes, 
matured with L1210 antigen 
and LPS, in combination with 
polyI:C and CTX 
therapeutic model 
 
s.c. 10 µg Combination therapy with 
polyI:C, CTX and 
exosomes leads to 
prolonged survival 
compared to the treatment 
alone 
[221] 
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MUC1 expressing 
CT26 colon 
carcinoma or B16 
melanoma  
HSP70 enriched tumour 
exosomes, heat induced 
therapeutic model 
i.d. 20 µg 3x every 
2nd week. 
HSP70 enriched 
exosomes prolonged 
survival even in 
allogeinic mice 
[154] 
J558 myeloma myeloma cell line J558 
expressing tumour antigen 
P1A, engineered to secret 
either IL-2, TNFα or IFNγ 
vaccination model 
i.v. 30 µg Exosomes from tumour 
cells expressing TNFα 
showed the best anti-
tumour immunity 
[228] 
3LL tumour, lung 
carcinoma 
Heat stressed tumour cell-
derived exosomes from 3LL 
lung cancer 
therapeutic model 
i.t. 5 µg  Heat stressed tumour-
derived exosomes attract 
DC and activate T cells 
more potently, reduce 
tumour growth 
[231] 
B16F1 melanoma MHCII expressing B16F1 
melanoma-derived exosomes 
(CIITA transduced) 
therapeutic model 
i.d. 5-20 µg  
 
Induce more activation of 
immune cells, Th1 
skewing 
[232] 
Xenograft breast 
cancer cells 
(HCC70) in 
RAG2–/– mice 
HEK293 expressing GE11 
which binds to overexpressed 
EGFR on tumour cells and 
transfected with let-7a miRNA 
therapeutic model 
i.v. 1 µg, 1 x/week 
for 4 weeks 
GE11 positive exosomes 
bind to tumour and 
reduce tumour growth via 
let-7a, let-7 expression in 
cancer cell lines alters cell 
cycle progression  
[233] 
Glioma xenograft 
model 9L 
MSC transfected with  miR-
146b plasmids, (mir146b has 
been shown to reduce cell 
motility) 
therapeutic model 
i.t. 50 µg  One i.t. injection of 
exosomes carrying mir-
146b led to reduced 
tumour growth in rats 
[229] 
B16 melanoma BMDC-derived exosomes 
loaded with OVA and αGC 
therapeutic model 
i.v. 40 µg, 1 or 2 
times 
Exosomes loaded with 
OVA and αGC prolonged 
survival, no induction of 
anergic NKT cells 
[222] 
A549 non-small 
cell lung cancer 
Rab27a overexpression in the 
human non-small-cell lung 
cancer cell line A549 
vaccination and therapeutic 
model 
s.c. 10 µg 4x 
before/after 
tumour injection 
Exosomes from Rab27a 
overexpressing cell line 
induce better DC 
maturation, more Th1 
cytokines and a stronger 
anti-tumour immunity 
[234] 
3LL tumour, lung 
carcinoma 
3LL lung tumour carcinoma 
cells transfected with CD40L 
vaccination and therapeutic 
model 
s.c. 10 µg exosomes activate DC 
more efficiently and 
induce more CTL leading 
to more efficient anti-
tumour immunity 
[235] 
human breast 
cancer cell line 
MDA-MB-231 
immature mouse DC cell line 
deliver doxorubicin (Dox), 
engineered to target integrins 
therapeutic model 
i.v.3mg/kg Exosomes containing 
Dox and a targeting 
domain induce slower 
tumour growth  
[236] 
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Table 3: Summary of results of exosome-based therapies in clinical trials 
 
1.5.3 Exosomes in Immune Suppression 
Tolerosomes. In 2001 it was described for the first time that OVA fed mice express MHC 
class II positive exosome like-vesicles in the plasma, which are able to induce tolerance and 
suppress OVA-specific immune responses in syngeneic mice [240, 241]. A similar study 
showed that plasma-derived exosomes from KHL (keyhole limpet hemocyanin protein) 
immunized mice are immunosuppressive in a delayed-type hypersensitivity model. This 
effect was dependent on antigen, MHC class II expression and FasL on intact exosomes. 
Interestingly, mechanical disruption of exosomes resulted in loss of the immunosuppressive 
activity [242]. It has been discussed that commonly encountered antigens induce 
immunosuppressive effects to reduce the risk of developing chronic inflammation and 
autoimmunity. Furthermore, exosomes isolated from bronchoalveolar lavage fluid of mice 
intranasally exposed to an allergen, induced lower IgE levels and Th2 cytokine levels in a 
mouse model of allergic airway inflammation [243].  
Mesenchymal stem cell-derived vesicles. Mesenchymal stem cells (MSC) have been reported 
to induce immunosuppressive effects and were used in phase I and II clinical trials in type I 
diabetes, Crohn´s disease and cardiovascular disease [244]. Interestingly, several studies 
describe that injection of conditioned MSC media suppressed inflammation as efficient as the 
MSC alone [245]. Later on, the effect was described to be exosome dependent. MSC-derived 
exosomes reduced infarct size in a mouse model of myocardial ischemia by reducing 
oxidative stress and promoting cell survival factors [246, 247]. 
 
Cancer type Exosome vaccine Injection route Clinical outcome Ref.  
Non-small cell lung 
cancer patients 
 
DC-derived exosomes 
loaded with MAGE 
tumour peptides 
therapeutic model 
s.c. (90%), i.d. 
10% 0.13×1014 
MHCII molecules 
No toxicity, poor MAGE-
specific T cell response 
[219] 
Metastatic 
melanoma patients 
DC-derived exosomes 
loaded with MAGE 
tumour peptides 
therapeutic model 
s.c. (90%), i.d. 
10%, 0.13 to 0.4 
×1014 MHCII 
molecules 
No toxicity, stable disease in 
one patient, no MAGE 
specific CTLs in the blood 
[237] 
Colorectal cancer 
patients 
Ascites-derived exosomes 
(Aex) in combination with 
GM-CSF 
therapeutic model 
s.c. 100, 200, 300 
or 500 µg Aex and 
50 µg GM-CSF 
Aex and GMCSF together 
induce cytotoxic T 
lymphocytes 
[238] 
Non-small cell lung 
cancer patients 
IFNγ matured monocyte-
derived DC 
therapeutic model 
i.d. Boost of NK cell activity, no 
tumour-specific T cell 
induction 
[239] 
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Exosomes in breast milk and pregnancy. Exosomes can be found in breast milk [248] and 
have been shown to induce regulatory T cells in vitro [139] and to carry immunomodulatory 
miRNA [249]. Pregnancy has been shown to alleviate different chronic inflammatory 
diseases like rheumatoid arthritis [250]. It is possible that placenta-derived exosomes can be 
part of the modification of the immune status of the mother. Expression of NKG2D ligand 
such as MICA/B on placenta-derived exosomes inhibit NKG2D expression on NK cell, CD8+ 
T cells and γδ T cells leading to reduced cytotoxic activity [251, 252]. Furthermore, placenta-
derived exosomes can alter gene expression in T cells [253] and inhibit T cell signalling via 
downregulation of CD3-zeta chain mainly on CD8+ T cells [254]. In addition, it has been 
shown that placenta-derived exosomes express FasL and TRAIL, which can induce apoptosis 
in Jurkat cells to induce an immune privileged site in the uterus [255]. Taken together, these 
results suggest that placenta-derived exosomes are playing an important role in influencing 
the immune status of the mother.  
Exosomes in transplantation. Immunosuppressive exosomes were used as treatment to reduce 
allograft rejection. Treatment with immature donor DC-derived exosomes in combination 
with a sup-optimal dose of rapamycin prolonged survival after heart transplantation 
significantly [256]. Similar results were obtained with treatment of DC-derived exosomes and 
a drug inhibiting DC maturation. The combination of exosomes and drug prolonged survival 
markedly compared to drug treatment alone [257].  
Regulatory T cell-derived exosomes. CD4+ Foxp3+ T cells express exosomes with 
immunomodulatory capacity. Rab27a/b silencing in Tregs leads to reduced exosome 
secretion and interestingly to enhanced systemic inflammation [258]. In addition, Treg-
derived exosomes inhibit CD4+ T cell activation and IFNγ and IL-2 production in vitro. This 
effect was inhibited following addition of a CD73 inhibitor [259]. The expression of CD39 
and CD73, enzymes involved in adenosine production, has been shown to be crucial for the 
immune suppressive function of Treg cells [260, 261]. Recently, certain microRNA in Treg-
derived exosomes have been shown to play an important role in immune modulation. miR-
155, Let-7d and Let-7b in Treg exosomes are important in reducing systemic inflammation 
[258]. Treg-derived exosomes were injected after kidney transplantation and led to prolonged 
survival and improved function of the transplant [262]. In conclusion, Tregs secrete 
exosomes, which may play an important role in systemic immune suppression and could be 
used as a therapeutic agent.  
Engineering of immune suppressive exosomes. Immature DCs carry low levels of MHC and 
costimulatory molecules on the surface and can be immunosuppressive. DC genetically 
modified to express IL-4 or FasL can suppress collagen induced arthritis [263, 264]. 
Interestingly, also exosomes from bone marrow-derived DC treated with IL-10 or genetically 
modified to express FasL can suppress collagen induced arthritis [265, 266]. The mechanistic 
effect for how these vesicles suppress the immune response is still unclear. However, the 
effect was MHC class II and antigen dependent. MHC class II deficient exosomes did not 
suppress inflammation whereas MHC class I deficient vesicles were functional [266]. In 
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contrast, Yu et al. described that exosomes isolated from DCs expressing membrane-
associated TGFβ inhibited progression of MOG-induced EAE in mice also in allogeneic mice 
[267]. 
 
1.6 TUMOUR-DERIVED EXOSOMES AND MICROVESICLES 
Exosomes play an important part in communication between cancer cells. Recent results 
suggested that exosomes are involved in cancer growth, tissue remodelling and metastasis. 
Cancer cells release large quantities of extracellular vesicles, which can be found in the body 
fluid of cancer patients. Blood plasma from melanoma cancer patients is enriched in 
exosomes compared to healthy controls and exosome concentration in the serum correlates 
with prognosis [268]. In addition, metastatic cancer cells release exosomes expressing high 
levels of ESCRT-related proteins which indicates a high production rate of exosomes [269]. 
Metastasis. Invasion and metastasis is the main treatment failure and connected with poor 
prognosis in cancer. Metastasis involves acquiring of migratory capacity, losing epithelial 
phenotype, dissemination and establishment at distant sites [270]. Tumour-derived exosomes 
(TEX) have been shown to facilitate the migratory capacity and to induce metastasis and 
invasion. Melanoma-derived exosomes home to the sentinel lymph node and induce changes 
in the gene expression profile of genes involved in cell recruitment, extracellular matrix and 
vascular growth factor production, all of which facilitates metastasis to the draining lymph 
node [143]. Interestingly, miRNA released in exosomes from cancer cells can bind to TLR, 
which leads to tumour promoting inflammation that favours metastasis and tumour growth 
[271]. Exosomes from highly metastatic melanoma cells educate bone marrow cells and 
induce a greater tumour growth and lung metastasis. Furthermore, the exosome-associated 
oncoprotein MET induces enhanced bone marrow cell mobilization [268] and tumour-
derived exosomes can directly promote specific organotrophic metastasis through organ 
specific expression of integrins [272]. Further understanding of the mechanism of how 
exosomes promote metastasis is needed to be able to therapeutically target the mechanism. 
Specific protein expression profile on TEX in the plasma of patients could be used as future 
biomarkers to distinguish patients with high metastatic burden from patients with low 
metastatic burden.  
Angiogenesis. Different studies have investigated the influence of exosomes on promoting 
angiogenesis in the tumour microenvironment. One of the first studies investigating the 
influence of MVs on angiogenesis showed that platelet-derived MVs transferred the CD41 
integrin to lung cancer cells and stimulated the MAPK pathway and led to an increase in the 
expression of specific matrix metalloproteases and cyclin D2 and upregulation of different 
angiogenic factors. [273]. Glioblastoma tumour cells release exosomes containing angiogenic 
factors and can stimulate endothelial cells to form tubules [142]. In addition, monocytes 
releasing exosomes containing miRNA-150 strongly induce endothelial tube formation and 
injection of anti-miR-150 into tumours in mice reduced formation of new blood vessels 
[274]. Human colon cancer-derived exosomes activate Egr-1, which leads to enhanced cell 
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migration of an endothelial cell line via the activation of ERK1/2 and JNK kinases [275]. 
Hence, exosomes influence the tube formation and the development of new blood vessels and 
thus contribute to tumour growth and invasiveness.  
Transfer of oncogenic proteins. Tumour-derived exosomes can transfer certain information 
from the parent cell to other malignant or normal cells. TEX can carry oncoproteins from the 
parent tumour cell and transfer these to other cells [276-278]. An oncogenic form of the 
epidermal growth factor receptor (EGFRvIII) can be transferred to cells lacking this mutated 
receptor, which in turn leads to upregulation of anti-apoptotic genes and to anchorage 
independent growth [279]. Furthermore, exosomes from a colon cancer cell line expressing 
mutant KRAS are able to transfer mutated KRAS to a cell expressing wild-type KRAS which 
leads to an enhanced three-dimensional growth [280]. Transfer of oncoproteins by exosomes 
to other cells can be a mechanism to transform normal growing cells into cancer cells and 
leading to better tumour growth. 
Breakdown of extracellular matrix (ECM). Exosomes and MVs can mediate metastasis by 
expressing enzymes important for extracellular matrix degradation to facilitate metastasis. 
EMPIRIN, a glycoprotein expressed by tumour cells, which induces expression of matrix 
metalloproteases in fibroblasts, has been shown to be shed in vesicles [281, 282]. Prostate 
cancer-derived exosomes can influence differentiation of mesenchymal stem cells to cells 
producing VEGF, HGF and metalloproteases [283]. 
Hypoxia. Hypoxia is a common hallmark of many tumours [284], it drives tumour formation 
and is associated with metastasis and poor prognosis [285]. Low oxygen levels in the tumour 
lead to changes in the expression of genes involved in angiogenesis, metastasis and invasion 
mediated by hypoxia inducible factor (HIF) [286]. Hypoxic breast cancer cells augment 
release of MVs by HIF-dependent upregulation of Rab22a. These hypoxia-induced MVs 
promote invasion and metastasis in a Rab22a dependent manner [287]. Several studies 
describe upregulation of exosome production under hypoxic conditions including expression 
of certain miRNA [288, 289] or IL-10/TGFβ [290, 291], which in turn leads to enhanced 
motility and endothelial tube formation and immunosuppression, respectively.  
pH. Low pH levels can be detected in the tumour microenvironment and might influence 
activities of enzymes involved in ECM degradation. Tumour cells release more exosomes 
under acidic conditions than in buffered conditions and, interestingly, these exosomes fuse 
more efficiently with the plasma membrane of tumour cells [292]. This might be a 
mechanism to enhance the transfer of proteins or RNA via exosomes in the tumour.  
 
1.6.1 Immune Suppressive Exosomes in Cancer 
Already in 1985 Poutiaska and colleagues showed that vesicles released by B16 melanoma 
cells can inhibit the antigen presentation capacity of macrophages leading to reduced CD4+ T 
cell activation [293]. Evading immune destruction and immunosuppression is a hallmark of 
cancer [294] and tumour cells develop strategies to regulate the immune system; mainly T 
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cells, DCs and NK cells. Tumour cells release exosomes and MVs which play an important 
role in immune escape. TEX express different immunosuppressive molecules, including 
checkpoint receptor ligands such as PD-L1, cytokines as TGFβ and IL-10 or ligands from the 
death receptor family such as FasL or TRAIL [295-297]. Furthermore, TEX can carry and 
transfer growth factor receptors such as EGFR (epidermal growth factor receptor) and Her-2 
(human epidermal growth factor receptor 2) [279]. All these factors have been shown to be 
involved in immunosuppression and tumour progression.  
In the peripheral blood of cancer patients the frequency of regulatory T cells 
(CD4+CD25highFoxp3+) is elevated compared to healthy subjects [298, 299]. TEX can induce 
regulatory T cells in vitro and increase their suppressive capacity. Tumour-derived vesicles 
(combination of exosomes, MV and apoptotic bodies) from ascites of ovarian cancer patients 
and from ovarian cancer cell lines contain TGFβ and IL-10. This promotes the expansion of 
regulatory T cells and enhanced their suppressive capacity by upregulation the expression of 
CTLA-4 and FasL [300]. Other studies investigated exosomes from different malignant 
effusions from cancer patients and showed that also patient-derived TEX can induce 
regulatory T cells through the expression of TGFβ [301]. The induction of regulatory T cells 
leads to a more immunosuppressive tumour environment which favours progression and 
metastasis.  
TEX can induce apoptosis in cells through the expression of FasL on the exosome surface. 
Melanoma cell line-derived exosomes express FasL and induce apoptosis in Jurkat cells, 
which might hinder lymphocytes from exerting their anti-tumour activity [296]. This might 
be a mechanism of the tumour to reduce the activity of cytotoxic T cells in the tumour and 
hence reduce anti-tumour immune responses. Similarly, plasma exosomes from oral 
squamous carcinoma patients express FasL, which can also induce apoptosis in Jurkat cell in 
a FasL dependent manner. FasL expression on exosomes correlates with the tumour stage and 
nodal involvement in these patients [295]. Furthermore, vesicles (combination of exosomes, 
MV and apoptotic bodies) from the sera from melanoma patients express the tumour antigen 
MAGE3/6 and FasL and inhibit CD8+ T cell proliferation and induce expansion of regulatory 
T cells [302]. TEX can influence the tumour microenvironment by impairing differentiation 
of human monocytes to DCs and induction of their differentiation into HLA-DRlow cells, 
which fail to upregulate costimulatory molecules. These DCs had a suppressive activity on T 
cell proliferation [303].  
NKG2D is an activating receptor expressed by NK cells, NKT cells, CD8+ T cells and γδ T 
cells. Stressed cells express NKG2D ligands such as MICA and MICB, which leads to 
recognition by immune cells and subsequent lysis [304]. Many tumour cells release exosomes 
expressing NKG2D ligands. The NKG2D ligand expressing TEX can bind to immune cells 
and interfere with the recognition of tumour cells by NK, NKT cells etc. leading to immune 
escape. TEX from several cancer cell lines and from the pleural effusion of mesothelioma 
patients induce down-regulation of NKG2D on NK and CD8+ T cells in a TGFβ dependent 
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mechanism, not even IL-15, a strong activator of NKG2D, could overcome this effect. [305, 
306]. 
 
1.7 URINARY BLADDER CANCER 
In Western countries, urinary bladder cancer has been the sixth most common cancer in men 
and the eighth in women. During the last years the incidence of bladder cancer cases has 
increased while the mortality has been decreasing. Risk factors include environmental, 
genetic and lifestyle factors, especially smoking [307]. 90% of all bladder cancers are 
urothelial cell carcinomas, only a few cases represent squamous cell carcinoma or 
adenocarcinoma. 70% of all bladder cancer cases/malignancies are diagnosed with non-
muscle invasive bladder cancer (NMIBC) with stage T1 and T2, around 30% with highly 
muscle invasive bladder cancer (MIBC) (stage T3/T4) (Figure 5). Non-invasive bladder 
cancer has a good prognosis after transurethral resection (TUR-B) and cisplatin-based 
chemotherapy or BCG installation. However, the immunological mechanism underlying a 
favourable cancer progression of BCG is not well understood [308]. Several studies show that 
T cells and NK cells are important in tumour eradication. MIBC is spreading into the 
underlying muscle tissue and can metastasize to draining lymph nodes or even more to distant 
sites. Muscle invasive bladder cancer patients undergo radical cystectomy, partial removal of 
the tumour is not recommended due to high recurrence rates [309]. These patients have a very 
poor 5 year survival even with an optimal treatment. The median survival time of patients 
with metastatic disease is 15 months.  
 
 
 
Figure 5: urinary bladder cancer stages, 
T1/T2 superficial bladder cancer, T3/T4 
invasive bladder cancer into the connective 
tissue and underlying muscle  
1.7.1 Exosomes in Urine from Urinary Bladder Cancer Patients 
In 2004 exosomes were described for the first time in urine [138]. Urinary exosomes derived 
from different tissues and cells throughout the renal tract from the renal epithelia, podocytes, 
collecting duct to the urinary epithelia [310]. Due to the easy access urinary exosomes have 
been discussed as a potential marker for pathophysiological states of the urinary tract. CD24 
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has been described to be a marker for urinary exosomes [311]. For a long time it was believed 
that urinary exosomes function as a transporter of waste products instead of lysosomal 
degradation. However, several studies describe a role for exosomes in the urinary system 
[138, 311] and in regulating parts of the nephron by transmission of aquaporin 2 [312]. 
Several studies have been published investigating urinary exosomes from prostate cancer 
(PCa) and renal cell carcinoma (RCC) patients [313, 314]. Exosomes from the urine from 
RCC patients are enriched in proteins which are involved in cell death and cellular movement 
compared to healthy controls [315]. However, few studies have been investigating the role of 
exosomes in urinary bladder cancer (UBC) patients. Several studies compared urine from 
bladder cancer patients with healthy volunteers and described specific proteins enriched in 
the urine of cancer patients. Proteomics analysis of urinary exosomes from bladder cancer 
patients show upregulated expression of MUC1, CD44 and CD73 compared to healthy 
controls [316]. 22 proteins in urinary exosomes from bladder cancer patients were not 
expressed in the urine of healthy volunteers. In addition, TASCD2, a protein already 
described to be upregulated in different carcinomas, was found to be enriched in urinary 
exosomes from UBC patients [317, 318]. Another study describes the protein EDIL-3 to be 
highly expressed in the urine of high grade UBC patients and to induce migration and tube 
formation in HUVEC cell line. Exosomes from bladder cancer cell lines where EDIL-3 was 
knocked down were not able anymore to induce angiogenesis [318]. Urinary exosomes from 
UBC increase expression of mesenchymal markers like snail, a-smooth muscle actin and 
S100A4 and decrease epithelial markers like E-cadherin in urothelial cells [319]. In 
conclusion, urine provides a great source for exosomes to study mechanisms involved in 
cancer progression and they could serve as a source for biomarkers. However, further studies 
need to be conducted to define markers and to study their influence on cancer progression.  
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2 THE PRESENT STUDY 
2.1 AIMS 
 
Paper I To investigate if dendritic cell-derived exosomes can be loaded with the NKT 
 cell ligand α-galactosylceramide and if these exosomes can induce NKT cell 
 proliferation,  overcome NKT cell anergy and potentiate an antigen-specific 
 anti-tumour immune response in a B16 melanoma model. 
Paper II To investigate if MHC class I molecules on exosomes are necessary to induce 
 an antigen-specific immune response in vivo and if MHC mismatched 
 exosomes can be used in cancer therapy.  
Paper III To determine if dendritic cell-derived microvesicles induce a qualitatively 
 different immune response compared to exosomes. 
Paper IV To reveal the proteomic profile of urinary- and tumour- derived exosomes from 
 patients with muscle invasive bladder cancer, to understand the metastatic 
 process and to identify a potential marker for malignancy and prognosis.  
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2.2 EXPERIMENTAL SETUP 
This part summarizes the most important methods used. The more detailed methods are 
described in each paper separately. 
2.2.1 Mice 
All experiments were approved by the Stockholm regional ethics committee. For the papers I 
– III the following mice have been used for analysis, C57Bl/6 and BALB/c mice were 
purchased at Taconic, MHCI-/- (H2Kb and H2Db gene kockout) were kindly provided by 
Klas Kärre, KI and bred at Karolinska Institutet, MTC. OT-I/RAG2-/- mice, transgenic for a 
TCR recognizing the SIINFEKL peptide from OVA with C57Bl/6 background; Vα14 
transgenic TCR mice on C56Bl/6 background; CD1d-/- on C57Bl/6 background lacking NKT 
I and NKT II cells.  
2.2.2 Bone Marrow-derived Dendritic Cell Culture 
Exosomes were isolated from the supernatant of bone marrow-derived DCs from C57Bl/6, 
BALB/c, CD1d-/- and MHCI-/- mice. Cells were cultured at 4 x 10^5 cells/ml in RPMI 1640 
(Thermo Fisher) complemented with 10 % FCS (HyClone), 1 mM sodium pyruvate, 50 mM 
2-ME (Sigma-Aldrich, St. Louis, MO), 100 IU/ml penicillin/streptomycin (Thermo Fisher) 
10 ng/ml IL-4 (Invitrogen), and 10% GM-CSF conditioned medium (generated from the 
A8653/X63 clone; a kind gift from Mattias Svensson, KI). On day 3 equal amounts of culture 
media were added. On day 6, ovalbumin (300 µg/ml) and/or α-galactosylceramide (100 
ng/ml) were added which was washed away after overnight incubation. On day 7, cells were 
plated out in complete media containing 30 ng/ml LPS and 10 % exosome-depleted FCS and 
incubated for 2 days. On day 9, exosomes were isolated from the supernatant as described 
below. 
2.2.3 Exosome Isolation  
2.2.3.1 Exosome isolation from DC supernatant and human urine 
Urine was collected during cystectomy of urinary bladder cancer patients, either directly form 
the ureter or before surgery from the urinary bladder. Supernatant/urine was spun at 300 x g 
for 10 min to remove the cells for FACS staining, at 3000 x g for 30 min to remove cell 
debris. After filtration through a 0.22 µm filter the supernatant was spun at 100´000 x g for 2 
hours (Beckmann, LXP, Ti45 rotor) and washed once with PBS. The exosome pellet was 
resuspended in a small volume of PBS and frozen at -80 °C until further analysis.  
2.2.3.2 Exosome isolation from tissue explants 
Tumour tissue and non-tumour tissue were cut into 20 to 30 mm3 pieces and were cultured in 
AimV media overnight. The next day the supernatant was spun at 3000 x g for 30 min with a 
subsequent filtration through a 0.22 µm filter. Exosomes were isolated by ultracentrifugation 
as described above.  
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2.2.4 Exosome Characterization 
There are several standard methods to characterize exosomes and microvesicles. This part 
summarizes the four main methods used in the papers.  
2.2.4.1 FACS 
Exosomes and MVs can be analysed by FACs to determine the surface proteins. Exosomes 
and MVs are bound to sulfate-aldehyde latex microsphere beads (4 μm, 1.3 x 109 beads/ml, 
Invitrogen). To select only CD63 positive vesicles, 30 µg latex beads were incubated for 30 
min with 30 µg anti-human CD63 antibody (clone H5C6, BD Pharmingen) following rotation 
overnight. After blocking with 100 mM glycine for 30 min, followed by washing with 0.5% 
BSA/PBS exosomes are stained with any fluorophore labelled antibody and run on any flow 
cytometer. This allows the analysis of one protein per staining and requires only 0.2 µg 
exosomes per staining. 
2.2.4.2 Western blot 
Certain proteins on/in vesicles cannot be detected by antibodies directly and need to be 
analysed by western blot. The proteins of exosomes/MVs are isolated by lysing the vesicles 
with RIPA buffer, sonication and vortexing. Exosomal proteins were run on Mini-Protean 
TGX precast gels (BioRad) and blotted to Trans-Blot Mini PVDF membranes using a Trans-
Blot Turbo System (BioRad). The blots were blocked with 5% - non-fat milk in PBST 
overnight at 4°C. The next day the antibody of interest was used to detect the protein, 
together with a matching secondary antibody. The blot was visualized by enhanced 
chemiluminescence (GE Healthcare) with a ChemiDoc imaging system (Biorad).  
2.2.4.3 Proteomics 
Mass spectrometry allows the analysis of the whole exosomal proteome by using only 50 µg 
of total protein. In paper IV the proteomic profiles of tissue- and urine-derived exosomes 
were analysed by the SciLife laboratory in Uppsala. Proteins were isolated in a urea 
containing buffer with sonication. After trypsin digestion, peptides were purified by a Pierce 
C18 spin column, dried and resolved in 0.1% formic acid. Peptides were separated in a 
reversed-phase C18-column and subsequently electrosprayed into a Q-Exactive Plus 
Orbitrap mass spectrometer (Thermo Finnigan). 
2.2.4.4 Nanoparticle tracking analysis 
The size distribution of a particle solution can be analysed by nanoparticle tracking analysis, 
nanosight (LM10HSB system, NanoSight, Amesbury, U.K.). The size of vesicles in liquid 
phase can be measured by the rate of light scattering and Brownian motion of the particle. 
The LM10 instrument allows an accurate measurement of the size distribution but delivers 
limited results when it comes to particle numbers in poly-dispersed samples.  
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2.2.5 Mouse Experiments 
2.2.5.1 In vivo proliferation 
40 µg of exosomes in 100 µl PBS were injected i.v. into C57Bl/6 mice on day 0. Mice were 
fed with BrdU (5-bromo-2'-deoxyuridine, Sigma) in drinking water (0.8 mg/ml BrdU in 
water supplemented with 2.5% sugar, sterile filtered 0.22 µm prior to use) to investigate in 
vivo cell proliferation. The BrdU containing drinking water was replaced every second day. 
On day 7, mice were sacrificed and spleen and blood was taken for further analysis. 
Splenocytes were stained according to the manufacture’s (BD Bioscience) protocol and 
analysed on Fortessa LSR.  
2.2.5.2 Tumour model 
B16F1 melanoma cells were cultured in RPMI supplemented with 10% FCS, 100 IU/ml 
penicillin/streptomycin (Thermo Fisher). Cells were cultured at 2 x 10^5 cells/ml and split 
every second day and washed twice with PBS before injection. 30´000 or 200´000 cells were 
subcutaneously injected into the flank of C57Bl/6 mice and tumour volume was followed 
until it reached 1000 mm3. 
2.2.6 Patients 
In paper IV, nine patients with invasive urothelial urinary bladder cancer (UBC) were 
recruited in 2014-2015. The clinical data is described in Table 4. All patients underwent 
primary transurethral resection of the bladder tumour (TUR-B) and clinical staging. Six 
patients received neoadjuvant chemotherapy (NAC) preceding radical cystectomy (RC). 
Three patients were diagnosed with concomitant prostate cancer.  
Table 4: Patient characteristics 
 
  
Patient Preoperative clinical stage Staging post-cystectomy Gender Age NAC/noNAC Number of Cycles Response Additional Information
1 cT2N0M0,G3 pT2N0M0 male 76 noNAC 0 /
2 cT2N0M0,G3 pT0N0M0 female 69 NAC 1 CR
3 cT2N0M0,G3 pT0N0M0 male 39 NAC 4 CR
4 cT2N0M0,G3 pT0N0M0 male 66 NAC 3 CR Prostatic cancer Gleason score (3+4=7)
5 cT2N0M0,G3 pT0N0M0 female 79 NAC 3 CR
6 cT2N0M0,G3 pT0N0M0 female 77 noNAC 0 /
7 cT2N0M0,G3 pT2bN0M0 male 65 NAC 4 SD
8 cT2N0M0,G3 pT0N0M0 male 76 NAC 3 CR Prostatic cancer Gleason score (3+3=6)
9 cT1N0M0,G3 pT0N0M0 male 57 noNAC 0 / Prostatic cancer Gleason score (3+3=6)
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2.3 RESULTS AND DISCUSSION 
The discovery of MHC class II molecules on B cell-derived exosomes in 1996 drew interest 
in the immunological society for immune cell-derived exosomes. Shortly after, Zitvogel and 
colleagues described that immunization with DC-derived exosomes can eradicate established 
tumours in mice [202]. However, several phase I clinical trials showed no induction of 
antigen-specific immune responses after autologous immunization with DC-derived 
exosomes loaded with tumour peptides [219, 238]. Therefore, the understanding of how to 
potentiate and design exosome-based vaccines is crucial for the development of new 
therapeutic approaches. In study I, II and III we are investigating how DC-derived exosomes 
and MVs function and how they can be modified to be used as an anti-tumour treatment.  
 
2.3.1 Co-delivery of α-Galactosylceramide and Antigen on Exosomes Induce 
Potent anti-Tumour Immunity (Study I) 
2.3.1.1 Rationale 
The induction of a potent anti-tumour immune response needs the engagement of multiple 
players in the immune system. We have shown that DC-derived exosomes loaded with 
peptides are not sufficient for inducing antigen-specific immune responses in vivo. However, 
loading of the whole antigen onto exosomes led to activation of CD4+ [320] and CD8+ T cells 
[203] in vivo. To further potentiate the immune response we loaded the NKT cell ligand αGC 
onto DC-derived exosomes and investigated whether T and B cell responses were amplified. 
αGC has drawn interest during the last years as a potent stimulator of NKT cells, followed by 
the production of a wide range of cytokines [107, 108], maturation and licensing of DCs and 
subsequent CD8+ T cell activation [321]. αGC induces anti-tumour immunity mainly through 
the secretion of IFNγ by NKT and NK cells and at later time points by production of IL-12 by 
DCs [119]. However, injection of soluble αGC into patients with solid tumours induced a 
transient increased cytokine production but clinical results were limited [134]. This might be 
explained by the low NKT cell numbers in cancer patients [322], exhaustion of NKT cells 
after several injections [112] and by suboptimal delivery to DCs. The uncontrolled uptake of 
free αGC by different cell types can be overcome by using a specific delivery system such as 
cells or nanoparticles. αGC-loaded DCs induce a better NKT cell response compared to 
soluble αGC alone [113, 323]. Similar results were seen when coupling αGC to nanoparticles 
[324]. In addition, antibody mediated targeting of αGC-loaded nanoparticles to DEC205 on 
DCs led to an increased NKT cell activation and prevented their hyporesponsiveness 
compared to non-targeted nanoparticles [325]. In conclusion, coupling of αGC onto 
nanoparticles induces better effects in vivo. Therefore, loading of CD1d-expressing exosomes 
with αGC would be a possibility to induce a more efficient anti-tumour response.  
2.3.1.2 αGC on exosomes activate NKT cells and potentiate adaptive immunity 
To investigate whether exosomes could be loaded with αGC, we first examined if exosomes 
from αGC-loaded DCs were able to activate NKT cell in vitro. We prepared exosomes from 
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BMDCs pulsed with αGC (Exo-αGC) or OVA antigen (Exo-OVA). Exo-αGC induced 
proliferation of Vα14 splenocytes (genetically modified to express only the Vα14-Jα18 TCR) 
and induced increased the numbers of IL-4 producing splenocytes measured by ELISPOT, no 
response was seen after Exo-OVA stimulation. In contrast, exosomes derived from BMDCs 
lacking the CD1d molecule (CD1d-/- Exo-αGC) induced less proliferation of NKT cells and 
less IL-4 producing splenocytes. This indicates that αGC is mostly but not exclusively bound 
to CD1d on exosomes and might be integrated into the exosome membrane or into the 
exosome lumen. Similar results were obtained in vivo in B6 mice. We injected 40 µg 
exosomes i.v. and fed the mice with BrdU to assess in vivo proliferation. NKT cells strongly 
proliferated in response to Exo(αGC-OVA) within the first three days and expressed high 
levels of IFNγ until day 5. No response was detected upon Exo-OVA or PBS injection.  
Interestingly, we also detected activation of NK cells already 1 day after Exo(αGC-OVA) 
injection. It has been shown that activation of NKT cells by αGC also leads to activation of 
NK cells already 90 min after αGC exposure mediated through IFNγ [110]. NK cells are 
important players for tumour killing and immune surveillance. They recognize, according to 
the “missing-self” theory, tumour cells if they downregulate MHC class I expression.  
The induction of tumour-specific T cells and tumour-specific antibodies is a major goal of 
cancer immunotherapy. However, strong stimuli are needed to overcome the 
immunosuppressive microenvironment in cancer patients. In study I we detected an amplified 
induction of OVA-specific CD8+ T cells 7 days after injection, which was dependent on αGC 
and OVA on exosomes. Injection of exosomes loaded with αGC and SIINFEKL did not 
induce antigen-specific T cells. Therefore, we can conclude that αGC does not override the 
dependency on whole OVA, and does not induce a polyclonal expansion of CD8+ T cells. 
The activation of OVA-specific CD8+ T cells was dependent on CD1d on exosomes. 
Injection of CD1d-/- Exo(αGC-OVA) showed significantly lower induction of SIINFEKL-
specific cells. 
Antibody-dependent cell cytotoxicity (ADCC) is an important mechanism in anti-tumour 
immunity. ADCC occurs when tumour-specific antibodies bind to the tumour cells and can 
be recognized by Fc receptors on immune cells such as NK cells, macrophages and 
neutrophils. The activation through the Fc receptor leads to release of perforin and granzyme 
and to destruction of the tumour cell membrane and finally to apoptosis. Interestingly, 
antibodies used in the clinic such as rituximab (anti-CD20 antibody), trastuzumab (anti-
HER/neu antibody) and cetuximab (anti-EGFR antibody) have been shown to mediate 
ADCC [326]. Therefore, we were interested if exosomes loaded with αGC induce a potent 
antigen-specific humoral response. Exo(αGC-OVA) induced strong proliferation of CD4+ T 
cells, which was dependent on iNKT cells in vivo since CD4+ T cell proliferation was 
abrogated in CD1d-/- mice. In addition, germinal center responses, including T follicular 
helper cells and germinal center B cells, were potentiated after Exo(αGC-OVA) injection 
compared to Exo-OVA or PBS. Interestingly, Th1 promoting IgG2c antibodies and OVA-
specific IgG antibodies were increased after Exo(αGC-OVA) injection, whereas levels of 
total IgG and IgG1 were similar. Induction of Th1 immunity is crucial for a potent anti-
tumour immune response. We conclude that αGC on exosomes boost the immune response 
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and induce specific B cell responses by activation of CD4+ helper T cells. In general, the 
advantage of using αGC on exosomes as an adjuvant is to induce a broad activation of 
different immune cells orchestrating a potent anti-tumour response.  
2.3.1.3 Exosome-associated αGC and OVA are more potent that soluble αGC and OVA in 
inducing adaptive immunity 
DC licensing through antigen-specific CD4+ T cells and the presence of TLR ligands is an 
important step for the induction of cross-presentation [327]. Nevertheless, also NKT cells can 
provide help for DC priming. Licensing of DCs through NKT cells requires presentation of 
the protein antigen and the glycolipid on the same DC [321]. Therefore, αGC and OVA 
loaded nanoparticles, and in particular exosomes, are likely superior to soluble antigens in 
delivering the protein antigen and the glycolipid on the same particle. We show that soluble 
αGC and OVA are potent stimulators of NKT cells, but are inducing less potent adaptive 
responses. γδ T cell, OVA-specific CD8+ T cell and CD4+ T cell proliferation was augmented 
after Exo(αGC-OVA) injection compared to soluble antigen (Figure 6). Furthermore, 
induction of germinal centers and OVA-specific antibody production was strongly enhanced 
after the second exosome injection. Thus, exosomes loaded with αGC and OVA can deliver 
strong signals directly to the same DC, which enables induction of licensed DCs and enables 
better cross-presentation. 
 
Figure 6: Exosome-bound αGC and OVA are more potent in inducing adaptive immunity 
compared to soluble αGC and OVA. Enhanced proliferation of iNKT and NK cells can be 
detected after soluble OVA and αGC injection. In contrast, γδ T cells, OVA-specific CD8+ T 
cells, CD4+ T cell responses are enhanced after Exo(αGC-OVA) treatment and diminished 
after soluble αGC and OVA injection, data is published in paper I 
2.3.1.4 Exo(αGC-OVA) administration does not induce anergic NKT cells and prolongs 
survival significantly in a B16 tumour model  
As already discussed previously, repeated injections of soluble αGC induces anergic NKT 
cells. Therefore, we wanted to investigate if two injections with Exo(αGC-OVA) (at day 0 
and day 14) leads to unresponsive NKT cells. Measurement of serum IFNγ levels one day 
after the second injection (d15) revealed higher IFNγ levels in the Exo(αGC-OVA) injected 
group compared to the group injected with soluble αGC and OVA alone. Hence, NKT cells 
are still able to produce cytokines after the second Exo(αGC-OVA) injection and are not 
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anergic. Furthermore, restimulation of splenocytes with αGC at day 21 showed more INFγ 
producing cells after Exo(αGC-OVA) injection compared to soluble antigen. In addition, 
glycolipid and SIINFEKL-specific T cells were more abundant. Two injections of Exo(αGC-
OVA) also increased percentages of germinal center B cells and antigen-specific IgG levels 
dramatically. This further demonstrates that exosome-associated αGC allows several 
injections and boosts the anti-tumour immune response. 
Finally, we were interested to know whether boosting of adaptive immunity by exosomes led 
to a prolonged survival in a B16/OVA model. Both one and two injections of Exo(αGC-
OVA) prolonged the survival significantly and led to a greater increase of tumour-infiltrating 
OVA-specific T cells and OVA specific IgG levels in the serum compared to soluble αGC 
and OVA alone (Figure 7). 
A B 
 
 
Figure 7: Exo(αGC-OVA) prolonged survival and induced more infiltrating antigen-specific 
T cells, mice were injected with 1 x 10^5 B16/OVA cells s.c. and treated with 40 μg 
exosomes on day 4 (1x injection) or day 4 and 11 (2x injections), mice were sacrificed when 
the tumour reached a volume of 1,000 mm3 A) Kaplan-Meier survival curve, B) quantitation 
of OVA-specific CD8+ T cell infiltration into the tumour, data is published in paper I 
2.3.1.5 Outlook Study I 
Our findings show that exosome-associated αGC and OVA do not induce anergic NKT cells 
and are superior in inducing an adaptive immune response compared to soluble αGC and 
OVA. However, the response might be even stronger if exosomes are directly targeted to the 
DC. As already mentioned above, DCs can also be licensed by NKT cells and co-delivery of 
the glycolipid and the protein antigen to the same DC could enhance activation of CD8+ T 
cells. Therefore, mechanism of DC targeting by exosomes also need to be investigated to 
potentiate exosomal cancer vaccines.  
Furthermore, when designing exosomal vaccines for therapy one also needs to take into 
consideration that the NKT cell levels in humans are reduced around 10 % compared to mice 
and that the variability in the numbers of NKT cells between patients is tremendous. Only a 
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subgroup of patients might respond to NKT cell mediated therapies, therefore selection of the 
right patient group is important for future therapeutic approaches.  
 
2.3.2 MHC Independency of Exosomal Vaccines (Study II) 
B cell- and DC-derived exosomes carry MHC molecules on the surface and are able to 
stimulate T cells directly. However, many of these studies used T cell lines in vitro and never 
non-primed cells in vivo [146, 206]. In addition, the presence of DCs in vitro greatly 
enhances T cell proliferation [207]. Hence, we questioned the importance of MHC molecules 
on exosomes to stimulate T cells and their direct stimulatory capacity in vivo. Several clinical 
trials using peptide-loaded DC-derived exosomes as anti-cancer vaccines showed limited 
effects; induction of antigen-specific CD8+ T cells was not detectable and clinical outcome 
was limited [219, 237, 238]. Furthermore, the use of the patient´s own monocyte-derived 
DCs might not be feasible due to clinical status and immunosuppression. Thus, allogeneic 
exosomes loaded with innate stimuli and antigens might be another possibility in cancer 
therapy.  
In study II we were interested in investigating if MHC molecules are needed to induce an 
antigen-specific T cell response in vivo and furthermore, if MHC mismatch leads to equal 
anti-tumour immunity in a B16 melanoma model. This would improve the feasibility of using 
exosomes as a vaccine and opens up new possibilities of using MHC mismatched parent cells 
as exosome producers. We isolated exosomes from BMDC from C57Bl/6 WT mice, MHCI-/- 
mice (C57Bl/6 background) and from BALB/c mice. First, we demonstrated that all 
exosomes shared phenotypic characteristics and expressed similar levels of costimulatory 
molecules such as CD40, CD80, CD86 and tetraspanins such as CD9, CD63 and CD81. In 
addition, CD1d expression on exosomes and OVA concentration were comparable on all 
exosomes types. Thus, we conclude that all exosomes are phenotypically similar but differ in 
their expression of MHC molecules. 
Intravenous injection of WT and MHCI-/- exosomes either loaded with OVA and αGC or 
OVA alone induced similar levels of OVA-specific CD8+ T cells in the spleen. Thus, we 
conclude that peptide/MHC complexes on exosomes are negligible to induce an adaptive 
immune response if the whole protein antigen is present. Furthermore, to test the feasibility of 
MHC mismatched exosomes in a tumour model we used exosomes from BALB/c BMDC. 
Here, both MHC class I and II are different from C57Bl/6 mice. Exosomes used in a clinical 
setting might not derive from the patient´s own cells and a MHC mismatch might occur and 
could even be beneficial. Indeed, injection of BALB/c exosomes led to comparable levels of 
OVA-specific CD8+ T cells in the tumour and OVA-specific IgG levels in the serum of these 
mice. Hence, MHC molecules present on DC-derived exosome are not necessary for the 
induction of an anti-tumour immune response.  
Different mechanisms of how DC-derived exosomes can stimulate an immune response have 
been discussed. MHC/peptide complexes on exosomes could directly bind and activate T 
cells (Figure 8A). However, the proliferation of T cells in the presence of exosomes only is 
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low and can be amplified by DC [207]. DCs could also take up exosomes, degrade the 
proteins and load the antigen on newly synthesized MHC molecules (Figure 8B). The third 
alternative is the recycling of exosomal MHC/peptide complexes and the presentation of the 
foreign MHC on the DC surface (Figure 8C) [209]. Study II demonstrates that mechanism B 
is most important in vivo (in our system).  
 
Figure 8: Different pathways of how exosomes could activate T cells, A) direct 
simulation through MHC/peptide complex, B) Degradation of exosome content and new 
loading of DC-derived MHC molecules, C) recycling of MHC/peptide complex from the 
exosomes to the DC surface. 
2.3.2.1 Outlook Study II 
We have shown that exosomes for cancer therapy do not need to be autologous. In contrast, 
allogeneic MHC molecules could even add to the adjuvant effect of the DC-derived 
exosomes. Therefore, the use of allogeneic exosomes in the clinic could be favourable. 
Interestingly, our preliminary results show that repeated injections of MHC mismatched 
exosomes led to a stronger immune response compared to injection of syngeneic exosomes 
(unpublished observations). The underlying mechanism of this effect and if allogeneic 
exosomes induce anti-MHC antibodies needs to be investigated. 
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2.3.3 Exosomes and Microvesicles Induce Qualitatively Different Immune 
Responses (Study III) 
In paper III we compared the immunostimulatory capacity of MV and exosomes isolated 
from the same cell side by side in vivo. To this date, MVs have not been extensively studied 
in vaccine settings. Therefore, we wanted to investigate if MVs and exosomes from the same 
DC induce qualitatively different immune response in vivo.  
Electron microscopy pictures of exosomes and MVs from preliminary experiments showed a 
clear contamination of the MV pellet with small vesicles. Therefore, we decided to purify the 
MV pellet with anti-tetraspanin beads to remove the small vesicles. Purification with anti-
CD63 and anti-CD81 coated beads did not show good purification results, while anti-CD9 
beads showed a reduced number of small vesicles measure by NTA. The shift in the particle 
diameter measured by NTA showed a successful removal of exosome-like vesicles 
expressing tetraspanins CD9, CD63 and CD81 measured by FACS after anti-CD9 bead 
purification.  
We show that MV and exosomes share phenotypic characteristics by FACS and expressed 
similar levels of CD9, CD54, CD80, CD86, MHC class I and MHC class II. However, CD63 
levels were lower in MVs compared to exosomes. In addition, phosphatidylserine expression 
measured by annexin V binding was higher in exosomes, however not significantly different 
to MVs.  
It has been shown that exosomes can be taken up via lipid rafts and by binding to annexins 
expressed on cells [328]. This could account for different biodistribution and uptake or 
clearance by different cell types. MVs and exosomes might also differ in their RNA content. 
This could be of importance since it has been shown that miRNA in exosomes from cancer 
cells can bind TLR7 from macrophages and induce expression of cytokines [271]. Their 
phenotypic differences and the influence on biodistribution, uptake and immune activation 
need further investigation. 
To investigate the in vivo stimulatory capacity of exosomes and MVs, we injected 40 μg of 
vesicles intravenously into C57Bl/6 mice and analysed the immune response 7 days after 
injection. Exosomes were superior in inducing antigen-specific CD8+ T cells compared to 
MVs measured by H-2Kb-pentamers and ELISPOT restimulation with SIINFEKL peptide. In 
contrast, MV induced significantly more plasma cells. However, both vesicle types induced 
similar levels of IgM antibodies in the serum, whereas only exosomes induced IgG2c and 
OVA-specific IgG antibodies. No differences were seen in total IgG and IgG1 levels. Hence, 
exosomes induced a Th1 biased immune response, similarly to what we have seen in paper I, 
whereas MV rather induced an unspecific activation.  
MV and exosomes might also differ in their biodistribution. Intravenously injected MV and 
exosomes will probably be captured in the marginal zone of the spleen. Depending on the 
size, surface charge and surface proteins they will be taken up and processed differently. DCs 
bind preferentially 100 nm sized particles [329]. Therefore, MV might be captured by 
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macrophages, which clear them from the blood circulation without inducing a potent immune 
response. Macrophages have been described to be important cells in the marginal zone to 
capture extracellular vesicles [163]. In contrast, exosomes might be taken up by DCs to a 
larger extent.  
Since exosomes were more potent in activating an antigen-specific immune response we 
were interested if both vesicle types carry similar amounts of OVA. Analysis by ELISA and 
WB revealed a much higher concentration of OVA in exosomes compared to MVs, both on 
the surface and inside. Therefore MVs might activate the immune system unspecifically and 
are not able to induce antigen-specific immune responses due to the low amount of antigen. 
The MR expressed on BMDC (discussed later) could influence the uptake and intracellular 
fate of OVA and the location in endosomes.  
 
2.3.4 Discussion Paper I - III 
2.3.4.1 Exosomes – Natural Liposomes 
Protein-based vaccines require an adjuvant to activate the immune system. Nanoparticle- and 
liposome-based vaccines can carry innate stimuli such as TLR ligands to activate DCs 
efficiently, leading to a potent immune response. At the same time, they are delivery vehicles, 
which can carry and transfer antigens. Exosomes can function as natural adjuvants and 
deliver innate stimuli and activate the innate immune response. In study I, we show that 
loading of αGC leads to efficient activation of NKT cells and to enhanced adaptive immunity. 
Interestingly, exosomes can transfer proteins and antigens to immune cells. The location of 
the antigen can be important for their immunogenicity. Exosomes can carry the antigen on 
the surface or inside, but only antigens on the surface are able to stimulate B cells directly. 
Exosomes used in study I, II and III carry OVA on the surface and might be able to activate 
OVA-specific B cells directly. Nevertheless, antigen delivery by exosomes might overcome 
the dilution of the antigen in vivo and enables the delivery of low amounts of antigen to 
antigen presenting cells.  
The lipid composition of exosomes is similar to cells. They express certain integrins and 
tetraspanins, which have been shown to be important in their biodistribution and cell uptake. 
As a natural vesicle, exosomes are negatively charged. In study III we show that exosomes 
and MV express negatively charged PS on their surface. In contrast, several studies have been 
using positively charged liposomes as vaccine adjuvants to enhance the interaction between 
cells and liposomes [330]. However, PS on liposomes has a potent adjuvant effect and PS 
positive liposomes are preferentially taken up by conventional DC [331]. In conclusion, 
exosomes express proteins and lipids, which are important for their uptake and can promote 
similar functions as liposomes. 
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2.3.4.2 BMDC-derived Exosomes and the Uptake of OVA 
In study I,II and III we used BMDC-derived exosomes loaded with OVA antigen. OVA was 
added to the culture at day 6 and incubated overnight. The next day cells were washed and 
the free OVA was removed and cells were cultured for two days in exosome-depleted media. 
The mechanism of the OVA loading process onto exosomes in DCs is unknown and the 
reason for the lower loading of OVA onto MVs also needs further studies.  
More is known about how free OVA is taken up by cells. In general, DCs take up soluble 
antigens through two different mechanisms, micropinocytosis or clathrin-mediated 
endocytosis. Macropinocytosis is a non-specific mechanism and mediates uptake through 
membrane ruffles [332]. In contrast, clathrin-mediated endocytosis is an active mechanism, 
which depends on cell surface receptors such as Fc receptors or the mannan receptors (a C-
type lectin receptor, MR, CD206) [333]. The uptake of OVA is mainly mediated via clathrin-
mediated endocytosis through the MR and to a lesser extent through macropinocytosis [334, 
335]. Interestingly, depending on the route of uptake, OVA peptides are preferentially loaded 
onto MHC class I or MHC class II molecules. Uptake of OVA via the MR leads to more 
cross-presentation, while uptake via macropinocytosis to more MHC class II loading. 
Importantly, mainly antigen which is taken up via the MR is found in early endosomes and 
can be cross-presented. This is not the case if it is taken up via scavenger receptors. 
Interestingly, only CD8+ DC express the MR [334, 335]. Hence, depending on the uptake 
mechanism, OVA is shuttled to different endosomal compartments. In our system, the uptake 
of OVA via the MR receptor might lead to exosome loading. We detect a great amount of 
OVA inside of exosomes (based on western blot results), thus, OVA needs to be released into 
the cytosol from the endosome to be loaded into the exosome lumen. Uptake through the MR 
leads to more cross-presentation and therefore to more OVA in the cytosol. However, in 
study III we did not detect OVA inside of MV. The process behind this discrepancy is still 
unclear and needs further investigation.  
OVA on the surface of our exosomes can also influence their biodistribution and uptake 
through the MR in vivo at the marginal zone. Interestingly, peptides and proteins conjugated 
to mannan stimulate CD4+ T cells much better compared to non-conjugated antigens [336]. 
Several clinical trials using MUC1 bound to mannan for DC- targeting showed promising 
results and the induction of humoral and cellular immune responses [337, 338]. Therefore, 
the importance of the MR receptor on the biodistribution and uptake of our OVA loaded 
exosome vaccines needs to be determined and compared with other antigens.  
2.3.4.3 General Problem of Tumour Vaccines  
For designing new tumour vaccines the knowledge of the tumour antigen is crucial. Very 
often, tumour antigens are endogenous proteins. Therefore, the presence of T cells 
recognizing these antigens seems impossible due to central tolerance and the deletion of self-
reacting T cells in the thymus. However, certain T cells escape central tolerance due to low 
expression of mainly carcinoembryonic and gamete antigens (major tumour antigens) in the 
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thymus. Unlike positively selected T cells, these tumour antigen-specific T cells express a 
low affinity TCR since high affinity clones are deleted in the thymus. In contrast, a vaccine 
against a virus activates virus-specific T cells in the periphery, which have not been selected 
in the thymus due to the foreign nature of the protein. Thus, it is difficult to design exosome- 
based cancer vaccines and to induce a potent immune response by using neoantigens 
expressed by the tumour. Furthermore, some tumours have a low mutation rate and therefore 
express low levels of neoantigens and are therefore not easily recognizable by the immune 
system. In addition, the use of self-antigens might need an even more personalized approach 
to detect specific neoantigens in the patients. In study I, II and III we have used OVA as a 
model for tumour antigen loaded onto exosomes. OVA can be used in very high 
concentrations which might not be feasible for clinical applications. Therefore, new antigen 
delivery methods for exosome loading need to be developed.  
Another problem when using tumour vaccines is the presence of regulatory T cells, MDSC 
and tumour-associated macrophages (TAM) in the tumour and high levels of immune 
suppressive cytokines like IL-10 and TGFβ in the tumour. In addition, TILs express high 
levels of checkpoint molecules which lead to immune escape. Therefore, targeting immune 
suppressive factors in combination with a vaccine might be a successful approach to 
overcome the immune suppressive microenvironment in the tumour. Several approaches are 
currently under investigation. Targeting immune checkpoints like CTLA-4 (ipilimumab) with 
monoclonal antibodies showed good clinical results in melanoma patients [61]. Targeting of 
Tregs with an IL-2-diphteria toxin conjugate led to a 16 fold increase in tumour-specific 
cytotoxic T cells in renal cell carcinoma patients [339] and COX-2 inhibitors suppressed 
MDSC and increased TILs in a mouse glioma model [340]. Targeting the microenvironment 
and immune suppressive cells in the tumour in combination with tumour vaccines might be 
successful. However, the balance between induction of a strong anti-tumour immune 
response and the development of autoimmunity needs to be considered.  
2.3.4.4 Future Perspectives – Exosomal Vaccines 
Cancer immunotherapy currently relies on strategies such as antibody-based therapies, 
cytokines and adoptive cell transfer. Exosome-based cancer therapy has shown limited results 
in clinical trials. However, in the last years the understanding of how to manipulate and 
engineer exosomes has increased rapidly.  
One of the major problems in designing exosomal vaccines is the delivery of antigens on or 
in exosomes. Since it has been shown that peptide loaded exosomes are not efficient in 
inducing specific immune responses in vivo, the loading of whole protein antigens needs to be 
further investigated. In paper I, II and III we added OVA to the BMDC culture to be loaded 
on exosomes. The disadvantage of this method is the huge protein amount needed. Therefore, 
new antigen loading methods needs to be developed to increase the feasibility of exosome-
based cancer vaccines. Antigen can be genetically coupled to tetraspanins to be exposed on 
the exosome surface. However, this method requires a stable transfection of a cell line, which 
secretes immunostimulatory exosomes. Until this day, it is not fully understood why certain 
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exosomes are immunostimulatory and others not. Interestingly, Hao and colleagues showed 
that DC-derived exosomes are superior in stimulating CD8+ T cells in vivo compared to 
tumour-derived exosomes loaded with the same antigen [230]. In paper II we show that the 
induction of an immune response is independent of MHC molecules if the whole antigen is 
present. Therefore, exosomes could possibly be isolated from engineered cell lines without 
the need for the patient’s own cells. This would also allow isolation of exosomes from large-
scale bioreactors, which would increase the particle numbers greatly. However, the 
understanding of the molecules needed to induce an immune response and the specific 
targeting of cells needs further investigation. 
CD169+ macrophages, subcapsular sinus macrophages in the spleen, capture B cell-derived 
exosomes. CD169-/- mice have a diminished immune response against antigen-pulsed 
exosomes [163]. In the tumour draining lymph nodes they clear and limit dissemination of 
tumour-derived vesicles [214]. Macrophages in lymphoid organs might limit the 
immunostimulatory function of DC-derived exosomes. Therefore, exosome targeting to 
specific immune cells or blocking of specific receptors on macrophages might induce more 
potent responses. Hence, the understanding to which cells and receptors exosomes naturally 
bind and how they are taken up would increase the knowledge for improving exosomal 
vaccine design. 
 
2.3.5 Exosomes from the Tumour Site Express a Malignant Memory 
Phenotype (Study IV) 
In paper IV we wanted to investigate the metastatic process induced by exosomes from urine 
and from the tumour site of urinary bladder cancer patients and if they express markers for 
diagnosis and recurrence.  
First, we needed to establish a protocol for exosome isolation from human tumour tissue. 
Tumour-derived exosomes were isolated from tissue explants from the tumour site and from 
healthy bladder tissue removed during cystectomy cultured for 24 hours in media. Exosomes 
released during this time were collected and analysed. Furthermore, we isolated exosomes 
from urine coming directly from the ureter and from the urinary bladder, collected during 
surgery. All patients underwent a TUR-B before cystectomy, a cytoscopic surgery where the 
tumour, or parts of the tumour, are removed from the bladder. We show that exosomes from 
the urine and from the tumour site express malignant phenotypes, even when no macroscopic 
tumour is left at the previous tumour site after TUR-B. We detect a separation of the urine 
whether it has been in contact with the tumour or not. We propose that exosomes express a 
metastatic memory in the tissue and these conditions might influence recurrence of 
macroscopic tumours.  
Tissue-derived exosomes separated according to malignancy and in dimension 1 correlated 
with gender, prostate cancer and number of NAC cycles. We could define 487 proteins in 
urine from the bladder and 30 from the tumour site, which are specific predictors of 
malignancy. Bladder urine and tumour site exosomes shared 6 proteins (ATP6V1A, Rab5C, 
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GNAS, BASP1, GNA13, HLA-DRB1). These 6 proteins have been described to be 
involved in cancer progression. Interestingly, even if no tumour is left the tissue- and urine-
derived exosomes express a carcinogenic phenotype which might be involved in the 
formation of pre-metastatic niche. They might derive from microscopic tumours or from 
epithelial cells affected by the tumour cells. ATP6V1A, an ATP-dependent proton pump, 
mediates acidification of intracellular organelles and it is expressed in the plasma 
membrane of invasive tumour cells and can mediate metastasis [341]. Rab5C, involved in 
fusion processes of intracellular vesicles, involved in metastasis and regulated EGFR 
activation [342]. GNAS and GNA13, proteins from the G-protein family, are signalling 
proteins and can express mutations in several malignancies.  
The proteins correlating with malignancy were involved in different pathways including 
metabolism, platelet activation, growth factors and the semaphoring pathway. Due to the high 
proliferation rate, cancer cells have a higher need for nutrients; they require rapid generation 
of ATP, increased synthesis of macromolecules and control of the redox status. However, it is 
not clear if these factors apply also for slow growing tumours in humans, since many studies 
have been examining in vitro cell cultures.  
One major metabolic phenotype of cancer cells is the shift from oxidative phosphorylation to 
glycolysis and the breakdown of glucose to lactate in an oxygen-independent manner. 
Therefore, the demand of glucose is much higher in cancer cells compared to normal cells, 
since glycolysis leads to production of less ATP compared to oxidative phosphorylation 
[343]. Production of lactate also supports the acid microenvironment seen in cancerous tissue. 
The enhanced metabolism also leads to production of NADPH, which is needed to prevent 
reactive oxygen species induced damage [344]. 
A second pathway involved was platelet activation. Platelets are secreted by 
megacaryocytes in the bone marrow. Their main function is to halt bleeding after injury. 
However, cancer patients often suffer from thrombosis and often very severely if they are 
diagnosed with metastatic disease [345]. Activated platelets can interact with circulating 
tumour cells and facilitate adhesion to the endothelium and subsequently extravasation and 
metastasis [346]. Several studies showed that platelet-derived microvesicles stimulate cell 
proliferation and matrix metalloprotease (MMP) expression, increased the adhesion to the 
endothelium and promoted metastasis in vivo [273, 347]. 
Semaphorins are a very diverse group of proteins and were first described to direct neuronal 
axons to the right target. More recently they have been described to either promote tumour 
progression or to function as tumour suppressors. They can affect tumour progression in 
different ways by promoting angiogenesis, recruiting bone marrow cells or directly 
targeting adhesion and cytoskeletal rearrangement of tumour cells, thus influencing cell 
attachment and migration [348]. The most studied semaphoring in cancer metastasis is 
semaphoring 4D (SEMAD4D) which can mediate angiogenesis and tumour progression in 
head and neck squamous cell carcinoma. Furthermore, it is highly expressed in transformed 
epithelial cells but not in non-invasive cells [349]. Exosomes from malignant bladder tissue 
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and bladder urine might contribute to tumour progression by activating the semaphorin 
pathway.  
Certain proteins were highly upregulated in the urine from the bladder compared to the 
urine from the ureter. Proteins which were already described in malignancies and could 
function as prognostic markers are: transmembrane protease serine 2 (TMPRSS2), acid 
phosphatase, prostate (ACPP) and phosphoglycerate mutase 1 (PGAM1). TMPRSS2:ERG 
fusion protein was described to be shed in prostasomes [350, 351]. ACPP was increased in 
the serum of prostate cancer patients and have been described to be associated with vesicle 
structures [352, 353]. PGAM1 expression in tissue has been described to correlate with the 
clinical status of the patient [354].  
Many proteins upregulated in urine and tissue might reflect an ongoing inflammation after 
TUR-B. Several complement proteins were upregulated in the bladder urine and proteins 
associated with eosinophils were upregulated in tumour site tissue. It was demonstrated that 
eosinophils infiltrate into the bladder tissue after TUR-B [355]. Therefore, Charcot-Lyden 
crystal galectin (CLC) and eosinophil peroxidase (EPX) expression in exosomes from the 
tumour site might reflect cell infiltration after surgery. Furthermore, carboxypeptidase M, a 
marker for macrophage maturation and mainly expressed by M2 macrophages could also 
reflect the ongoing inflammation in the tissue or the accumulation of tumour-associated 
macrophages. Interestingly, this protein has never been described in urine from UBC 
patients.  
In this study we have shown that exosomes can be distinguished according to their 
proteomic profile if they are coming from the ureter or have been in contact with the 
tumour site, or if they were isolated from the previous tumour site of from healthy bladder 
tissue. Furthermore, patients with concomitant prostate cancer express a specific exosomal 
phenotype in the bladder exosomes. We conclude that even when no tumour is left 
exosomes express a malignant memory phenotype which might be involved in recurrence 
and progression.  
Our unveiling of malignant memory in the tissue exposed to the tumour and even in urine, 
suggests that the tissue is altered and prepare to harbour new tumour cells. The fact that this 
is detected in the exosomes from the tissue, suggests that exosomes play a role in this 
process and might contribute to metastasis formation at distant sites. Further understanding 
of this process might give us the tools to reverse or inhibit the process of relapse and 
metastasis.  
2.3.5.1 Future Perspective - Tumour-derived Exosomes 
Tumour-derived exosomes have been shown to be involved in different processes in tumour 
progression. They influence the tumour microenvironment, promote metastasis in distant 
lymph nodes and organs, transfer oncogenic proteins, breakdown extracellular matrix 
proteins and induce and immune suppressive environment.  
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Invasion and metastasis are the main treatment failures and connected with poor prognosis. 
The understanding of how exosomes and microvesicles promote metastasis and help inducing 
the pre-metastatic niche at distant sites could help developing new therapeutics. TEX mediate 
organ-specific metastasis through expression of specific integrins and induce changes in gene 
expression in distant organs [272]. However, the mechanism behind the metastasis promoting 
effect is not known and whether specific receptors on endothelial cells or immune cells take 
up exosomes specifically needs to be determined.  
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